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EPID EM IO LO G Y OF H O N G  K O N G  INFLU EN ZA  
TU ESD AY, OCTOBER 14, 1969 
8:45 A.M .— 12:30 P.M.
Session I
W. Charles Cockbum, P. J. Delon, and W. Ferreira; Geneva, Switzerland
Origin and World Progress of the Epidemic
by
T h e  W orld H ealth  O rganization’s in fo r­
m ation on influenza is obtained th rough  its 
Influenza Program m e w hich was established 
in  1947. Its objectives are the identification, 
rap id  characterization, an d  d istribu tion  of 
em erging strains, and  the collection an d  dis­
sem ination of virological and epidem iologi­
cal inform ation in the W H O  W eekly E p i­
demiological Record. C ollaborating in the 
program m e are 85 national influenza labo­
ratories in 55 countries and two in te rn a­
tional influenza centres.
T h e  H ong Kong strain  of virus A2 may 
have orig inated  somewhere in m ainland 
China, b u t this is not certain. I t  first came 
to general notice when an epidem ic of 
500,000 cases occurred in H ong Kong in 
m id-July 1968. Strains isolated in H ong 
Kong were characterized in  the in te rn a­
tional centres and  distribu ted  to interested 
laboratories by mid-August.
Infection spread rapidly  to Singapore, the 
Philippines, T aiw an, V ietnam , Malaysia, 
T h ailan d , Ind ia  (M adras and Bombay), and 
the N orthen T erritories of A ustralia—as 
happened in  the 1957 pandem ic. Later, 
however, progress slowed down, and except 
in  the U nited  States of America little  
spread to new areas occurred u n til the be­
ginning of 1969. In  the U.S.A. an extensive 
epidem ic commenced in Novem ber and  was 
associated w ith a large num ber of "excess
deaths." T h is experience was different from 
th a t of all o ther countries. In  Europe sev­
eral large epidemics were reported , b u t in 
general the incidence as m easured by 
school-absence and  sickness-absence in in ­
dustry was relatively low and  no general 
rise in num bers of deaths was reported.
In  the southern  hem isphere, outbreaks 
have been reported  recently in  A ustralia, 
New Zealand, South Africa, and  several 
countries in South America. T h e  disease 
has been clinically m ild  and  th e  reported  
incidence no t particularly  high.
T h e  most im portan t epidem iological ob ­
servations so far are, first, the contrast b e­
tween the rap id  spread in south and sou th ­
east Asia and the sm ouldering spread in 
most o th er areas and, second, the contrast 
between the high m ortality  in the U.S.A. 
and the low m ortality  in o th er countries. A 
satisfactory explanation  of these differences 
would lead to increased understanding  of 
the natu ral history of influenza and m ight 
also lead to the developm ent of better 
measures for prevention, control, o r trea t­
m ent.
T h e  W H O  Influenza Program m e a t­
tained its m ain objective—the early isola­
tion, characterization, and  d istribu tion  of 
the s tra in—b u t there is scope for im prove­





W. K. Chang; Hong Kong
National Experience—Hong Kong
by
H ong Kong has experienced two large 
epidemics of influenza in the- past 12 years. 
On both  occasions, the epidem ic was caused 
by a new varian t of influenza A virus and 
was followed by a pandem ic spread. T he 
Asian flu of 1957 apparently  originated in 
the central m ain land  of the People’s R e­
public of China, and the epidem ic of 1968, 
possibly, could have come from the same 
source. P rio r to the ou tbreak  in H ong 
Kong, travellers reported  an  increase in the 
incidence of influenza-like infection in the 
neighboring Chinese province. However, 
virus isolation from the incom ing travel­
lers was not attem pted  to confirm the re ­
ports.
T h e  frequent daily com m unications by 
cargo boats and passenger trains from 
China predisposes H ong Kong to influenza 
spread. Being a tourist centre and a free 
port, H ong Kong is also a likely place for 
virus exchange w ith o th er parts of the 
world by a ir  and sea. T h e  m ajor factor 
facilitating the local dissem ination of virus 
is over-population. In u rb an  areas, the 
average population  density is 500 per acre. 
U nder this crowded living condition, an ep i­
demic due to a new varian t is explosive and 
readily  recognizable. Overcrowding can p ro ­
voke an outbreak in a sub-tropical country 
even in  the hot sum m er season.
T h e  1968 epidem ic was first recognized
on Ju ly  13 when the num ber of patients 
w ith influenza-like symptoms tu rn in g  up 
a t the governm ent clinics suddenly in ­
creased. T h e  increase was greatest in the 
week of Ju ly  27 and subsided gradually in 
the following 3 weeks. T h e  outbreak lasted 
for about 6 weeks. An estim ated one-fifth 
of the population  was involved, and the 
m ortality  rate was very low. All age groups 
were equally affected. T h e  clinical sym p­
toms were considered m ild, lasting from 
3 to 5 days.
T h e  first virus strain  was isolated in p r i­
m ary monkey kidney tissue cu ltu re on July 
17. I t was prelim inarily  identified as in ­
fluenza A2 virus. T h e  virus was inhibited  
to a titre  of 1 in 80 by the polyvalent A2 
antiserum  which had an H I titre  of 1 in 
640 against A2/67 strains. In  view of its 
antigenic deviation, the virus was im m edi­
ately dispatched in the form of infected 
tissue cu ltu re to the W orld Influenza Cen­
tre in London. Five m ore lyophilized strains 
were sent to the W orld Influenza Centre 
and the Interna tional Influenza Centre for 
the Americas, A tlanta, du ring  the following 
week. T h e  strain was la ter shown to be a 
d istinct antigenic varian t of the A2 virus, 
and on August 16, the W orld H ealth  O r­
ganization issued a w arning of the potential 




H ideo Fukum i; Tokyo, Japan
National Experience—Japan
by
D uring and since the unusual influenza 
epidem ic in H ong Kong in July 1968, many 
cases of influenza were im ported into Japan , 
not only from H ong Kong b u t also from 
areas where the epidem ic had spread. A 
few m ore than ten virologically confirmed 
cases were scattered from their entrance 
ports to various parts of the country. Ex­
cept for those which were im ported, no 
cases of influenza due to the H ong Kong 
virus were reported anywhere in Japan 
un til the end of September.
At the beginning of October 1968, the 
first outbreak of influenza, confirmed v iro­
logically as due to the H ong Kong virus, 
was reported in a prim ary school in Tokyo; 
thereafter, the num ber of such outbreaks, 
mostly in prim ary, m iddle, and high schools 
in the Tokyo-Yokohama area, gradually in ­
creased. By the end of October, Osaka and 
some o th er cities were involved. T h e  ep i­
demic thus consisted of m ulticentric o u t­
breaks.
Generally speaking, influenza outbreaks 
due to the H ong Kong virus started to oc­
cur in Japan  a t the beginning of October
1968, b u t the speed at which the virus 
spread did not appear to be as rap id  as is 
usually the case when a new antigenic v ari­
an t has appeared. Moreover, the areas to 
which the virus was reported to have spread 
were m ainly cities w ith large populations; 
namely, the Tokyo-Yokohama, Osaka-Kyoto- 
Kobe, and Nagoya areas. T hough  scattered 
outbreaks, confirmed as due to the H ong 
Kong virus, were reported  in o ther areas, 
the epidem ic seems to have been reluctant 
to spread to neighboring country places. 
T h is contrasts sharply with the pa tte rn  of
the type B influenza epidem ic which oc­
curred in Jap an  at approxim ately the same 
time and spread to both urban  and rural 
areas.
T h e  extent of the spread of the H ong 
Kong influenza epidem ic in Japan  was 
estim ated by means of serological surveys, 
i.e., by calculating the m orbidity rate of 
H ong Kong influenza in various po p u la­
tions on the basis of antibody rises against 
the new varian t after the epidem ic sub­
sided at about the end of M arch 1969. 
Such experim ents were carried ou t in sev­
eral populations whose living and environ­
mental conditions varied. O ur experience 
suggests that in populations having a cer­
tain level of an tibody  against the A2 in ­
fluenza virus due to earlier experience, the 
disease ceased to spread and the epidemic 
subsided. For exam ple, in the Self- 
Defense Forces camps, 70 to 80% of the 
total population  had experienced infection 
by the end of the second wave of A2 in ­
fluenza, whereas am ong people working in 
health  centers the rate was about 40 to 50%. 
Com pared to these rates, the attack rate 
du ring  the H ong Kong influenza epidem ic 
was much lower: for instance, serological 
tests perform ed in A pril 1969 showed the 
rate in Self-Defense Forces camps to be 30 
to 40%.
In conclusion, after H ong Kong influenza 
appeared, there were many chances for the 
virus to be im ported into Japan  from ep i­
demic areas abroad. Nevertheless, in Japan 
the epidem ic had a fairly delayed start, 





Robert G. Sharrar; Atlanta, Georgia, U.S.A.
National Experience—United States
by
Docum ented A 2/H ong K ong/68 influenza 
activity began in early Septem ber as isolated 
outbreaks in m ilitary installations in the 
Pacific Division and isolated cases in the 
civilian population  predom inantly  in east­
ern  m etropolitan  areas. Seeding of the virus 
continued du ring  the following 6 weeks, 
and by O ctober 17, 1968, 15 States reported  
isolated docum ented cases. Most of these 
patients were, or had contact w ith, persons 
re tu rn in g  from the Far East.
T h e  first com m unity-wide outbreak, as 
determ ined by school and industrial a b ­
senteeism in the continental U nited States, 
began in Needles, California, du ring  the 
week ending O ctober 19. Activity developed 
in five additional States in the M ountain 
and Pacific Divisions du ring  the following 
3 weeks and in two States in the M iddle 
A tlantic Division and one State in the West 
N orth  Central Division du ring  the follow­
ing fourth  week. O utbreaks were reported  
in eight of the nine geographic divisions by 
Decem ber 7. By December 28, all 50 States 
experienced influenza outbreaks. Twenty- 
nine States reported th a t peak activity oc­
curred between Decem ber 15 and January  4, 
and activity in an additional 11 States 
peaked du ring  the week ending January  11. 
D uring January  influenza activity declined 
except for sporadic outbreaks in po p u la­
tions not previously involved.
T h e  N ational H ealth  Survey reports th a t 
53.5 m illion persons, or 27% of the n o n in ­
stitutionalized population , experienced an 
influenza-like illness between O ctober 1 and 
December 31, 1968. D ata for 1969 are not
available. Schools were reporting  absentee­
ism rates as high as 50%, and some com m u­
nities were experiencing attack rates of 
approxim ately 20%. Prelim inary data  from 
Kansas City indicate th a t the age-specific 
attack rates were relatively uniform  for all 
age categories.
Pneum onia-influenza m ortality  statistics 
from 122 selected U.S. cities can be used as 
an indicator of influenza activity. Excess 
m ortality  was first evident du ring  the week 
ending December 7, rose sharply  over the 
following 6 weeks, and peaked du ring  the 
week ending January  11 when a total of 
1,166 excess deaths were reported. T h is peak 
occurred 1-3 weeks after most States re ­
ported greatest activity. Pneum onia-influ­
enza m ortality  returned  to expected levels 
d u ring  the week of M arch 29. T o tal m or­
tality statistics also reflect influenza activity. 
D uring this influenza season, total excess 
m ortality  for 122 U.S. cities was estim ated 
to be 19,500 compared to a total excess 
m ortality  of 26,800 from 114 U.S. cities d u r­
ing the 1957-58 pandemic.
Isolated cases of influenza B were docu­
m ented in November and December; how ­
ever, outbreaks did not become evident 
un til late January  and February. T h e  re ­
ported illness predom inantly  involved ele­
m entary school children, and caused absen­
teeism rates of 25-45% in some areas. 
T w enty States reported one or more o u t­
breaks, and some influenza B activity was 
docum ented in 37 States. T h e  most wide­
spread B activity occurred in eight conti­
guous States in the Midwest.
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T h e  H ong Kong varian t of influenza virus 
A2 was isolated in B ritain  for the first tim e 
from a child resident in London who d e­
veloped a respiratory illness early in A u­
gust 1968. T h e  first outbreak was reported 
in Septem ber from a residential school in 
the South of England. From Septem ber to 
D ecember outbreaks occurred in several 
residential institu tions in various parts of 
the country, b u t there was no evidence of 
general spread in the com m unity u n til after 
Christmas.
In  the last week of December 1968 there 
was a steep rise in new claims to sickness 
benefit, particularly  in the W est M idland 
region, w here a m axim um  for the w inter 
was reached in the week ending January  7,
1969. D uring m id-January  new claims to 
sickness benefit fell in all regions, b u t rose 
again, in the N orthern  region du ring  the 
last week of Jan u ary  and in all o ther re ­
gions of England and in W ales and Scot­
land du ring  the first half of February. A 
peak for the country  as a whole was reached 
in the week ending M arch 4, 1969, and new 
claims to sickness benefit continued to re ­
m ain substantially  above their usual levels 
u n til the first half of A pril.
T h e  incidence of influenza in practices 
reporting  to the Royal College of G eneral 
P ractitioners began to increase in the first 
week of January  1969 and rose slowly to 
a peak of just over 150 cases per 100,000 
population  in the week ending M arch 11. 
In England and W ales (population ap prox i­
m ately 48.7 m illion) deaths assigned to in ­
fluenza and influenzal pneum onia rose very 
slowly from the beginning of the year to
reach a m axim um  of 125 in the week end­
ing M arch 28.
T h e  num bers of influenza virus A infec­
tions, confirmed by virus isolation or sero­
logical investigation, which were reported 
by the Public H ealth  L aboratory Service, 
began to increase in the last week of D e­
cem ber 1968 and rose rapidly to a peak of 
161 cases reported in the week ending Ja n ­
uary 31, 1969. A fter a fall in the first half 
of February, the num ber of reported  cases 
again rose and was m aintained for six suc­
cessive weeks, from late February to early 
April, w ithin a range of 125 to 161 per 
week. T h e  num bers then fell steeply, 
though isolations of influenza virus A con­
tinued to be reported  from specimens re ­
ceived as late as May. All strains of in ­
fluenza virus A investigated were sim ilar 
to A 2/H ong  Kong/1968. T hro u g h o u t the 
w inter there was little  evidence of influenza 
virus B infection.
Com pared w ith previous epidem ic w in­
ters, the prevalence of influenza during  
th a t of 1968/69 rose to only a m oderate 
height in any one week, b u t extended over 
an unusually long period—from late D e­
cem ber to early A pril. T h e  total m orbidity, 
as estim ated by excess new claims to sick­
ness benefit, was sim ilar to th a t of the p re ­
vious w inter of 1967/68 in which a sharp 
outbreak of influenza virus A2 infection 
occurred. T h e  relatively leisurely progress 
of the 1968/69 epidemic was accompanied 
by no sudden or excessive dem ands either 
on medical practitioners or on the hospital 
services. T h e  m ortality  was substantially 
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A new influenza epidem ic broke ou t in 
H ong Kong in 1968 against a background 
of the w aning influenza A2 epidem ic which 
had spread over 40 countries and territories 
of the world. T h is epidem ic was caused by 
a new varian t of influenza A2 virus desig­
nated as A 2/H ong  Kong/68 virus. Epidem ic 
outbreaks associated w ith this virus were 
registered in almost all countries of sou th ­
east Asia and in Oceania du ring  July- 
September. L ater on the new varian t was 
transported  to the U nited States by air 
and sea. In Septem ber of 1968 separate 
foci, m ore often of a family character, ap ­
peared in European countries. D uring  the 
first q u arte r  of 1969, the U nited  States, 
Canada, and all countries of Europe were 
involved in an epidem ic wave of influenza 
due to  the A 2/H ong Kong/68 virus.
T h e  appearance in 1957 of the pandem ic 
strain  of influenza A2 virus resulted in four 
epidemics in the U.S.S.R. T h e  fifth p an ­
demic wave was observed in the w inter of
1967, bu t it was of a m ixed etiology, since 
influenza B virus circulated a t the same 
time as influenza A2 virus in many towns. 
Cases of illness associated w ith influenza 
virus A 2/H ong Kong/68 in the U.S.S.R. 
were registered in the m iddle of December,
1968, in one of the schools in Moscow and 
am ong adu lt contingents in the Moscow 
region. However, the infection did not 
spread rapidly. Almost sim ultaneously, i.e., 
du ring  the second 10-day period of Decem­
ber, an increase in influenza m orbidity  was 
observed in the central Asiatic towns of
Frunze and D ushanbe where strains of in ­
fluenza virus A 2/H ong Kong/68 were re ­
covered. A peak in the incidence of the 
disease was registered in the th ird  10-day 
period of December. In  January  the ep i­
dem ic involved the Republics of Central 
Asia and the Caucasus and began move­
m ent through the center of the European 
p a rt of the U.S.S.R. to Moscow, L enin­
grad, and T allin . In February, the epidem ic 
spread over the Baltic area, Byelorussia, 
U kraine, and M oldavia and subsequently 
spread along travel routes.
In  Moscow and L eningrad influenza m or­
bidity  started to increase from approx i­
mately January  6, 1969. A peak in incidence 
was registered in Moscow on Jan u a ry  27 
and in Leningrad on January  28, 1969. T he 
dura tion  of the epidem ic in towns was 
approxim ately 50-80 days. On the whole, in 
the U.S.S.R. the epidem ic lasted about 4 
m onths. Therefore, the intensity of the rise 
and fall of the epidem ic wave was re la ­
tively gradual. T h e  age d istribu tion  of the 
disease was not in the least usual, i.e., in 
most towns children under seven m ade up 
14 to 25 percent of the total num ber of the 
registered cases.
Dynamics of the curve of influenza inci­
dence, a fluctuation of the percentage of 
the population  affected, as well as an u n ­
usual age d istribu tion  of the disease ap ­
parently  m ight be explained by the ap ­





Experience with Hong Kong Influenza in Tropical Areas 
by
Edward L. Buescher; Washington, D. C., U.S.A.
A lthough influenza has been repeatedly 
recognized in resident populations of tro p i­
cal areas, descriptions of m ajor epidemics 
have been confined to incidences of re ­
ported  disease, its sequellae and com plica­
tions, and its chronological progression in 
and between various countries. R eports of 
clinical disease prevalence d u rin g  the 1957 
(Asian) epidem ic suggested th a t attack 
rates in tropical countries were higher, 
com plications m ore frequent, and dissemi­
nation  of virus m ore rap id  than  in coun­
tries of the n o rth  and south tem perate 
zones.
D uring  the late sum m er and early fall of
1968, in troduction  of the significantly vari­
an t H ong Kong virus into tropical Asia and 
C entral America m ade possible two as yet 
unpublished studies of influenza infection 
and disease. One of these from the South 
East Asia T reaty  O rganization Medical R e­
search L aboratory (Smith, T . J., Olson, 
L. C., K andel, G. E., and Snitbhan, R.) d e­
scribes the in troduction  and progression of 
infection th rough  a population  of approx i­
m ately 6,000 U. S. servicemen resident in a 
single com m unity in T h ailan d . H ong Kong 
virus was apparently  in troduced into the 
com m unity in early  August by flight crews 
re tu rn in g  from o th er countries in Asia 
w here influenza was occurring. D uring the 
next 3 m onths, 8% of the population  con­
tracted disease severe enough to require 
relief from duty, and by Novem ber 1, at 
least 12% of the population  (as determ ined 
by follow-up serological survey) had been 
infected. Disease was relatively m ild, and 
there were no untow ard sequellae or com­
plications. Earlier rou tine im m unization
w ith vaccines which d id  not contain the 
epidem ic virus strain  had no apparent 
effect upon occurrence or severity of disease. 
T h e  epidem ic tended to peak in late August 
and early September, b u t significant nu m ­
bers of new cases continued to occur daily 
through October; thus the epidem ic p ro p a­
gated slowly and was different from the 
m ore precipitous epidemics seen du ring  the 
w inter of 1968 in tem perate zones.
In  contrast, ano ther study from the M id­
dle America Research U nit (Zachary, I. 
H., and Johnson, K. M.) showed th a t H ong 
Kong virus was rapidly  dissem inated 
through both indigenous and U.S. p o pu la­
tions of the Panam a Canal Zone during  
Septem ber-Novem ber 1968. A pparently  in ­
troduced by steam ship crews re tu rn ing  
from Asia, the virus rapidly  established i t ­
self in both populations. Clinical attack 
rates were h igher (approxim ately 50%) in 
both adu lt indigenous and select U.S. per­
sonnel of the Zone than were those ob­
served in T hailand , and these h igher dis­
ease rates were supported by the results of 
a postepidem ic serological survey.
Infection  was less frequent in children 
(approxim ately 30%), b u t a greater p ro p o r­
tion of infected children became ill than 
adults, and the reported  incidence of com­
plications in both  children and adults was 
less than  th a t observed in Panam a during  
the 1957 epidemic.
T hus, the rates a t which the same virus 
was disseminated am ong populations resid­
ing in different tropical areas varied and, 
in this respect, patterns of infection and 
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Critical Evaluation of the Surveillance of Influenza 
by
Alexander D. Langmuir and Jere Housworth; Atlanta, Georgia, U.S.A.
Surveillance, as recently defined by the 
W orld H ealth  O rganization, consists of the 
cu rren t collection, the careful evaluation, 
and the p rom pt dissem ination of all p e rti­
n en t data  regarding the occurrence of a 
disease. T h e  inform ation developed through 
surveillance should be d istribu ted  no t only 
to health  officers and others responsible for 
or concerned w ith the control of disease, 
b u t also in appropria te  form to the general 
public.
A global event of the m agnitude of the 
1968-69 pandem ic of H ong Kong influenza 
presents a massive challenge to the ade­
quacy of the existing surveillance system. 
It has varied in the extrem e. T h e  collection 
of essential laboratory  inform ation about 
the virus and its im m unological character­
istics has been coordinated th rough  the 
W H O  and its in ternational centers and col­
laborating  laboratories. T h e  prom pt, accu­
rate, and extensive knowledge resulting 
therefrom  has m ade possible the m anufac­
tu re  in large quan tity  of vaccines con ta in­
ing the specific new strain.
T h e  collection of p ertin en t and clinical 
epidemiological data  has been n either as 
adequate nor as consistent. L ittle  in ­
form ation regarding the relative severity of 
the clinical disease o r the character or 
seriousness of bacterial com plications has 
been m ade available, even in the U nited 
States w here an extensive surveillance n et­
work for epidem iological and laboratory 
d ata  existed. From inform ation available 
from many parts of the world it has not 
been easy to d iscrim inate sporadic single
cases or small localized outbreaks from com­
m unity-wide epidemics or w idespread n a ­
tional involvem ent. Present m ethods of 
influenza surveillance need m uch im prove­
m ent.
T h e  most practical, widely applicable, 
and in ternationally  com parable index of 
the extent and severity of epidem ic in ­
fluenza is excess m ortality . W illiam  Fan- 
developed this m ethod to a high degree of 
perfection during  an epidem ic in L ondon in 
1847. Essentially the same m ethod was used 
to describe the pandemics of 1889-92 and 
1918-19. Since 1918 excess m ortality  has 
been a standard  surveillance procedure in 
the U nited  States, b u t it is not in common 
use elsewhere.
A com parison of excess m ortality  in the 
U nited States w ith England and W ales since 
1957 reveals th a t influenza epidemics have 
been generally associated w ith m arkedly 
h igher m ortality  in England and Wales, 
w ith one notable exception. D uring the past 
year in the U.S.A. the H ong Kong strain 
has caused an extensive epidem ic w ith  high 
excess m ortality , whereas in England and 
W ales the increase in m ortality  has been 
m inim al in spite of w idespread identifica­
tion of the virus. T h e  reasons for these 
differences rem ain obscure. Experience d u r ­
ing the w inter of 1969-70 will be watched 
w ith interest.
More extensive use of curren t m ortality  
data  th roughou t the world would greatly 







P R O P E R TIE S OF T H E  H O N G  K O N G  INFLU EN ZA VIRUS  
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General Characteristics of the Hong Kong Virus 
by
Marion T . Coleman and Walter R. Dowdle; Atlanta, Georgia, U.S.A.
Session 11
Experience w ith the H ong Kong influenza 
variants in 1968-69 perm itted  observation 
of the biological characteristics of these 
strains un d er laboratory conditions. Some 
of their properties w hich have practical 
usefulness in the laboratory are reported.
U nlike A2 strains of the past few years, 
H ong Kong virus strains were readily iso­
lated  in bo th  eggs and  prim ary rhesus 
m onkey kidney tissue cultures. H em agglu­
tin ins were detectable w ith bo th  chicken 
and guinea pig erythrocytes. T h e  hem ag­
g lu tin in  titers of allanto ic fluids on in itia l 
harvest were usually adequate for identifi­
cation of most isolates by hem agglutination 
inh ib ition  (HI) tests.
Early electron m icrographs of the Hong 
Kong variants revealed both  spherical and 
filam entous forms w ith m orphological struc­
tu re  typical of influenza virus particles. 
A ntigenic structure of the variants has been 
defined by com plem ent fixation (CF) as 
sharing the soluble antigen common to 
viruses in the influenza A group. T h e  n eu ­
ram inidase of the H ong Kong strains re ­
sem bled o th er A2 strains, and varying rela­
tionships were found w ith hum an A2 and 
anim al influenza viruses by H I tests.
T h e  spectrum  of nonspecific serum in ­
hib itors of H ong Kong hem agglutinins 
found in norm al sera of hum ans and  several 
anim al species was different from th a t of 
earlier A2 strains. H um an and rab b it serum 
inhibitors were removed by treatm en t w ith 
receptor destroying enzyme (RDE). Perio­
date or trypsin-periodate reduced nonspe­
cific inhibitors from ferret and horse sera. 
Kaolin absorption was required  to remove 
inhibitors from guinea pig sera. Nonspecific 
inhibitors were not encountered in monkey 
and goat sera and rarely in  chicken sera. 
Some low passage level H ong Kong strains 
were m ore sensitive to nonspecific serum 
inhibitors than  o ther strains.
T h e  efficiency of H I and CF tests for d iag­
nosing infection was evaluated on paired 
sera of 163 adults from populations experi­
encing H ong Kong influenza outbreaks. 
Serodiagnosis by H I was the m ore efficient 
m ethod in th a t 22% of conversions (four­
fold or greater increases in antibody titer) 
detected by H I were not recognized by CF. 
Since 8% of the conversions were detected 
by CF only, the use of both  tests was re ­




Antigenic Relationships of the Hong Kong Virus Hemagglutinin to That of 
Other Human Influenza A Viruses 
by
Walter R. Dowdle, Marion T . Coleman and Elmer C. Hall; Atlanta, Georgia, U.S.A.,
and
Violeta Knez; Cordoba, Argentina
Session II
T h e  m agnitude of antigenic change of 
the H ong Kong strains from the earlier in ­
fluenza A2 strains was com pared w ith  p re ­
vious antigenic changes am ong the type A 
viruses. R epresentative type A strains re ­
covered from hum ans du ring  the years 1933 
th rough  1969 were exam ined by reciprocal 
hem agglutination-inhibition  (HI) tests w ith 
antisera produced in chickens. Phenogram s 
or family trees were constructed by using 
num erical taxonom ic m ethods based on 
cluster analysis of sim ilarity coefficients.
A phenon line corresponding to negative 
or zero correlation in the H I test pheno- 
gram  divided the 27 influenza A strains 
into two m ajor groups—one consisting of 
all strains isolated p rio r to the 1957 Asian 
pandem ic and the second consisting of all 
strains isolated since th a t time. Bases for 
add itional subdivision were less clear, bu t 
strains could be fu rth e r  divided by a rb i­
trarily  selecting certain  levels of correlation. 
A phenon line draw n at the next m ajor 
level of correlation divided the strains into 
three groups corresponding generally to 
subtypes AO, A l, and A2. A phenon line at 
the correlation level separating  the H ong 
Kong strains from earlier A2 strains re ­
sulted in a fu rth e r  subdivision of the 27 
type A strains into a m inim um  of six or a 
m axim um  of 10 groups.
A phenogram  constructed from reciprocal 
neutralization (N) tests w ith a sm aller nu m ­
ber of influenza A strains was sim ilar to 
th a t obtained by H I. T h e  neuram inidase - 
inh ib ition  (NI) phenogram  was also 
sim ilar in th a t only two m ajor groups 
were observed.
T h e  use of num erical taxonom ic m ethods 
to establish the antigenic position of H ong 
Kong-like strains fu rth er illustrates the in ­
adequacy of the present system of nom en­
clature. T h e  antigenic dissim ilarity between 
AO and Al seen in phenogram s constructed 
from reciprocal H I, N, and NI tests is of 
far less m agnitude than  th a t between Al 
and  A2 and  should not be given equal 
emphasis. T h e  degree of antigenic d is­
sim ilarity between the H ong Kong-like 
strains and the early A2 strains is even less 
than  th a t between AO and A l, and the A3 
appellation  proposed by some investigators 
cannot be supported on antigenic grounds.
Yet there is an undeniable need to dis­
tinguish PR /8-like strains from F M /l-like  
strains and H ong Kong-like strains from 
earlier A2 strains, as well as others, past 
and future. T o  do this, some new system of 
identification is required . A pplication of 
num erical taxonom ic m ethods provides a 




Antigenic Relationships of the Hong Kong Virus Neuraminidase 
to That of Other Human Influenza A Viruses 
by
Jerome L. Schulman and Edwin D. Kilbourne; New York, New York, U.S.A.
G enetic recom bination of influenza v i­
ruses may result in the form ation of an ti­
genic hybrids com bining in ‘the envelope 
of the recom binant virus the hem agglutinin 
of one paren ta l virus and the neuram inidase 
of the other. Such reciprocal recom binants 
have greatly facilitated the study of an ti­
genic relationships am ong influenza viruses 
by segregating and dissociating the two 
surface proteins of the virus th a t are p r i­
m arily responsible for the serologic reac­
tions of in tact viruses. T h is result is im ­
portan t, for although the neuram inidase is 
quantitatively  less represented on the virion 
surface than  the hem agglutin in  and does 
not partic ipate in conventional pre-inocula­
tion virus neutralization  reactions, specific 
antiserum  to the enzyme may cause hem ag­
g lu tina tion  inh ib ition  (HI) of in tact virus; 
conversely, antiserum  specific for the hem ­
agglutin in  may in h ib it the hydrolytic ac­
tivity of viral neuram inidase (El) through 
steric h indrance when in tact virus is the 
enzyme source.
H ybrid ization  of six influenza A2 strains 
(A 2/Japan /305 /57 , A 2 /T a iw a n /l/6 4 , A 2/ 
I tsukaichi /1 /65, A 2/ Mon tevideo/2208/67, 
A 2 /E ng land /10 /67 , A 2 /T ex as/2 /6 8 ) and 
H ong K o n g /16/68 virus w ith AO/NWS led 
to the isolation of seven recom binants 
bearing the NWS hem agglutin in  (AO) and 
the neuram inidase (E) of each of the A2 
or H ong Kong viruses (AOEI, A0E2, etc.) 
and seven reciprocal recom binants con­
ta in ing  A2 or H ong Kong hem agglutin in  in 
com bination w ith the NWS enzyme (e): 
(A21e, A22e, etc.). Specific antisera were 
then produced to all paren ta l and recom­
b in an t viruses, and their antigenic relation ­
ships were defined by H I, E l, p laque in h ib i­
tion (PI), and p laque size reduction (PSR)
tests. (PI and PSR perm it the comparison 
of H I and  E l activity, respectively, in the 
same test system). Antisera to all six A2 
viruses inh ib ited  the neuram inidase activ­
ity of all AOE recom binant viruses includ­
ing AOE(HK). However, as reported  
earlier, (Schulman and K ilbourne, Proc. N at. 
Acad. Sci. 1969) great variation  in enzyme 
cross-reactivity was dem onstrated between 
earlier (1957-64) strains and la ter (1965- 
68) viruses, including H ong Kong. D rift of 
the hem agglutin in  antigen was also dem on­
strated  in H I tests, b u t this variation  was 
independent of and  not concordant w ith 
the change in enzyme antigenicty.
S im ilarity coefficients of HK virus w ith 
the six A2 strains determ ined by H I and 
E l tests revealed identity  of the H K  n eu ­
ram inidase w ith the enzyme of the 1967-68 
A2 viruses bu t little  cross-reactivity of the 
hem agglutinins. These findings were con­
firmed in the p laque system in w hich a n ti­
sera to all A2 paren ta l viruses induced 
PSR of AOE(HK) virus (to greater tite r 
w ith 1967-68 antisera), b u t no PI of either 
H Ke or the paren ta l HK strain  was induced 
at the lowest d ilu tions tested. Furtherm ore, 
h igh tite r antiserum  to the paren ta l HK 
virus had no p laque in h ib itin g  (PI) activ­
ity w ith any of the A2e recom binants 
(which contained hem agglutinin of the 
1957-68 period b u t not the A2 enzyme).
In  sum mary, cross-reactivity of HK virus 
and virus of the A2 sub-types is entirely d e­
pendent upon and m ediated th rough  the 
viral neuram inidase and not th rough  the 
hem agglutinin. T h e  neuram inidase of the 
HK virus is slightly cross-reactive w ith the 
neuram inidase of o lder A2 strains and is 





Antigenic Relationships of the Hong Kong Virus Hemagglutinin 
to That of Animal Influenza Viruses 
by
Bela Tumova; Prague, Czechoslovakia, and B. C. Easterday; Madison, Wisconsin, U.S.A.
T h e  origin and evolution of antigenic 
changes in influenza virus type A are still 
poorly understood, and several proposed hy­
potheses do not satisfactorily explain the 
appearance of either the varian t or the 
novel subtypes. T h e  hypothesis of a com­
mon origin of anim al and hum an type A 
influenza viruses has received considerable 
support in recent years w ith the recovery of 
a num ber of strains from different anim al 
species related to hum an influenza viruses 
of the A2 subtype by one or both  envelope 
antigens—hem agglutinin and neuram in id ­
ase.
T h e  present study dem onstrates relation­
ship in  envelope antigens of six hum an A2 
strains isolated in the years 1957-1968 (in ­
cluding A 2/H ong K o n g /1/68), two strains 
of A /E quine-2  virus isolated in 1963, and  7 
avian influenza viruses isolated in Europe, 
N orth  America, and the U kraine in the 
years 1960-1967.
A ntigenic relationship  am ong the strains 
was determ ined on the basis of hemag- 
g lu tination-inh ibition , virus-neutralization,
strain  specific com plem ent-fixation, and 
neuram inidase-inhibition  tests.
N orth  American avian influenza strains 
Turkey/M assachussets/65, T urkey/W iscon- 
sin /66, T u rk cy /C alifo rn ia/64 , and the I ta l­
ian strain  D uck/Italy /574/66 are antigen- 
ically related to hum an A2 influenza viruses 
by hem agglutinin and neuram inidase. None 
of these viruses is antigenically related  to 
the A /E quine-2 /63  strains, D u ck /U k ra in e / 
2/60 and 1/63, and A 2/H ong K ong/1/68. 
However, A 2 /H ong  K o n g /1/68 has n eu ra­
m inidase sim ilar to th a t of o ther A2 strains 
isolated in previous years.
Definite relationship  was shown between 
the hem agglutinin of A /E quine-2 /63  strains, 
A 2/H ong K ong/1/68, D uck /U kraine/2 /60  
and 1 /63 in hyperim m une and postinfecti- 
ous sera by means of three different sero­
logical tests. Common neuram inidase was 
dem onstrated only between A /E quine-2 /63  
strains and the duck strains from the 
Ukraine.
T h e  significance of these findings and its 
in te rpreta tion  w ith respect to the ecology 




Antigenic Relationships of the Hong Kong Virus Neuraminidase 
to T ha t of Animal Influenza Viruses 
by
Geoffrey C. Schild; London, England
T h ere  is now m uch evidence th a t the 
haem agglutinin and neuram inidase form 
im m unologically and m orphologically dis­
tinct com ponents of the influenza virus en ­
velope. T o  be comprehensive, studies on 
im m unological relationships between sub- 
type specific antigens of different influenza 
viruses should therefore involve studies on 
virus enzyme in addition  to haem agglu­
tin in . In the present study the n euram in i­
dase of the A 2/H ong  K ong/1/68  varian t 
was com pared w ith th a t of form er A2 
viruses and of influenza viruses of avian, 
equine, and porcine origin.
T h e  neuram inidases of representative A2 
virus strains isolated in 1957, 1964, 1966, 
and 1967 variants were com pared w ith th a t 
of the H ong Kong varian t in enzyme- 
inh ib ition  tests w ith antisera prepared  by 
hyperim m unizing rabb its w ith purified 
neuram inidase or w ith concentrated and 
purified virus particles. T h e  results were 
expressed as the serum d ilu tion  inh ib iting  
enzyme activity by 50% after incubation 
for 16 hours a t 4°C. T h e  tests dem onstrated 
considerable im m unological differences in 
the enzymes of A 2 /S in g ap o re /l/5 7  and 
A 2/H ong K ong/1/68. H igh-titred  a n ti­
serum against A 2 /S in g ap o re /l/5 7  reacted 
to only low titres against A 2/H ong K ong/
1 /68 enzyme, whereas antiserum  to H ong 
Kong virus failed to neutralize the enzyme 
of A 2 /S in g ap o re /l/5 7 . Virus strains A 2/ 
E ngland /12 /64 , A 2/E ngIand/66 , and A 2/ 
T ok yo /3 /6 7  contained enzymes which cross­
reacted to some extent w ith both 1957 and
1968 variants. Im m unological relationships 
between the enzymes of the various A2 
viruses were also studied in im m uno-double- 
diffusion tests w ith antiserum  prepared 
against purified neuram inidase preparations 
using m ethods described by Schild and 
Pereira (1969). In these tests all A2 viruses 
reacted sim ilarly. T h e  precip itin  lines 
showed reactions of com plete identity  when 
the different A2 virus strains were com­
pared in the same test. H um an  AO or A1 
virus strains failed to react w ith an ti A2 
neuram inidase antiserum . T h e  differences
in specificity of the im m unoprecip itin  and 
enzym e-inhibition tests are difficult to u n ­
derstand. However, the results of the im ­
m unoprecip itin  tests suggested th a t all the 
A2 viruses tested shared enzymes of sim ilar 
basic structure, whereas enzym e-inhibition 
tests appeared to indicate possibly m inor 
im m unological differences in the enzymes.
In  previous studies enzym e-inhibition 
tests have indicated im munological re la ­
tionships between hum an and anim al in ­
fluenza A virus which were no t apparen t 
from the results of haem agglutination- 
inh ib ition  tests. Pereira, T um ova, and 
W ebster (1967) found th a t an avian virus 
A /T urkey/M assachusetts/65  contained an 
enzyme immunologically related  to th a t of 
A 2/S ingapore/l/57  virus and Schild, Pe­
reira, and Schettler (1969) described an in ­
fluenza virus of duck origin which con­
tained an enzyme im munologically related 
to th a t of hum an influenza AO and A1 
viruses. Reciprocal enzym e-inhibition tests 
were carried ou t in which H ong Kong virus 
neuram inidase was com pared to th a t of 
representative strains of avian, equine, and 
porcine influenza A viruses. U nlike A2/ 
Singapore neuram inidase, the enzyme of 
A 2/H ong Kong showed no cross-reaction 
with th a t of A /T urkey/M assachusetts/65 . 
However, two different duck influenza virus 
strains were found to contain enzymes re­
lated to th a t of the H ong Kong virus, b u t 
these failed to cross-react w ith H ong Kong 
in haem agglutination-inhibition  tests. A l­
though in haem agglutination-inhibition  
tests A 2/H ong Kong cross-reacts w ith 
Equine-2 virus strains, enzym e-inhibition 
tests failed to indicate serological relation­
ships between the enzymes of these viruses 
or th a t the enzyme of H ong Kong was 
related to th a t of a swine influenza virus 
(Sw ine/Cam bridge/39).
Schild, G. C. and Pereira, H . G., (1969). 
J. Gen. Virol., 4, p. 555.
Pereira, H. G., Tumova, B. and Webster, 
K. G., (1967). Nature, Lond., 2 /5 , p. 982. 
Schild, G. C., Pereira, H. G. and Schettler,
C. H., (1969). Nature, Lond., 222, p. 1299.
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Session II
Experimental Influenza Virus Infections in  M an and Horses 
by
J . A. Kasel; Bethesda, Maryland, U.S.A., and R. B. Couch; Houston, Texas, U.S.A.
T h e  recognition of an antigenic relation ­
ship between the hem agglutinins of A / 
Equine-2 virus isolated from horses in 1963 
and a type A2 virus which caused epidem ic 
illness in hum an populations in 1968 and
1969 suggested th a t interspecies spread of 
influenza virus may occur in n a tu re  and 
result in the emergence of new strains of 
virus in m an and horses.
Because of the possible biologic im por­
tance of this relationship for hum an influ­
enza, an investigation was conducted to 
assess the effect of inoculation of volunteers 
w ith equine influenza virus and of subse­
q uen t challenge w ith hum an type A2 virus. 
A sim ilar study was conducted in horses 
except th a t the virus challenge sequence 
was reversed.
Fifteen serum  neutralizing  antibody- 
negative adu lt m ale volunteers were inocu­
lated w ith A /E q u ine-2 /M iam i/63  influenza 
virus, and virus shedding ensued in all 
subjects. Illness developed in 13 persons, 
the most common clinical response being 
a febrile illness indistinguishable from 
naturally  occurring hum an influenza. Four­
teen of the 15 individuals exhibited  a rise 
in serum antibody tite r to the infecting 
strain  and, of these, nine developed a 
heterologous antibody response to A 2/H ong 
Kong/68 influenza virus. A fter adm inistra­
tion of A 2/H ong  K ong/68 virus to 10 se­
rum  antibody-negative Chincoteague ponies 
(Equus caballus), there was virus shedding 
from nine and a febrile response in six. 
Four of the anim als developed a rise in 
antibody tite r to the hum an strain, bu t 
none exhibited  an antibody response to 
A /E quine-2  virus.
W hen the 15 hum an subjects previously 
inoculated w ith equine virus were chal­
lenged w ith A 2/H ong  K ong/68 virus, the 
frequency of illness and the ex ten t of virus 
shedding was lower than  th a t which oc­
curred among 20 control individuals. Im ­
m unity against challenge was found to be 
related to the level of serum antibody titer 
to A 2/H ong K ong/68 virus which developed 
after equine virus infection. Only those 
volunteers who lacked or had low levels of 
serum antibody experienced infection. C hal­
lenge with A /E q u in e -2 /M iam i/6 3  virus of 
10 ponies previously inoculated w ith A 2/ 
H ong K ong/68 virus in the absence of any 
m easurable levels of serum antibody to the 
hum an strain  and five control anim als re ­
sulted in significantly less shedding of virus 
am ong the form er group of anim als. Two 
ponies with a p rio r exposure to A 2/H ong  
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F. M. Davenport, E. Minuse, A. V. Hennessy, and T . Frands, Jr.;
Ann Arbor, Michigan, U.S.A.
Interpretation of Antibody Patterns of Man: I. In  the United States
by
I t  has been shown th a t the m ajor antigens 
of the strains of the in itia l infections of 
childhood perm anently  orient the antibody 
form ing mechanisms so th a t on subsequent 
exposure by vaccination or infection with 
different strains of influenza virus of the 
same type, antibody against the original 
infecting strain  is vigorously reinforced. 
Owing to antigenic shifting, the indelible 
im p rin t of different cohorts of the po p u ­
lation is oriented to different families of 
strains. Consequently, a serologic recap itu ­
lation of a popu lation ’s past experiences 
w ith influenza viruses may be constructed 
by delineating  the age d istribu tion  of 
specific antibodies now reacting w ith p ro to ­
type strains.
Criteria for the delineation of an a n ti­
body p a ttern  have been progressively d e­
veloped. A t present four are in use. T h e  age 
d istribu tion  of a p articu lar antibody should 
correlate w ith w hat is known about the 
periods of epidem ic prevalence of influenza. 
Moreover, w ith the passage of tim e, the 
antibody pa tte rn  should shift in concord­
ance w ith the num ber of years th a t have 
elapsed between the two serological surveys. 
T h e  specificity of the antibodies should be 
established by the use of m ore than  one 
serologic m ethod. N eutralization tests and 
Drescher's photom etric test for defining 
strain  specific antibody have proven to be
highly useful for differentiating  between 
antibody patterns found w ith homologous 
and heterologous strains. Finally, a direct 
test of the validity of the recap itu lation  can 
be carried out by ascertaining the antibody 
response of different cohorts of the po p u ­
lation to m onovalent influenza virus 
vaccines.
In  the present study the age d istribution  
of H I H ong Kong antibodies was as­
certained w ith the Aichi strain  in sera 
collected in 1958 and in 1966. In  both 
collections a high frequency of antibodies 
was found in the sera of persons born  before 
the early 1890's. T h e  antibodies of this 
cohort were shown to neutralize virus in 
ovo and to react specifically in the D rescher 
photom etric test. T h e  an tibody  response to 
m onovalent A 2 /A ich i/2 /6 8  and A /E quine- 
2 /M ilfo rd /2 /6 3  vaccines was ascertained in 
subjects born in the intervals 1928-1937, 
1888-1901, and 1879-1888. A fter adm inistra­
tion of both  vaccines the Aichi antibody 
titers were the highest in specimens ob ­
tained from persons born between 1879 and 
1888.
Clearly, H ong Kong-like viruses have 
existed du ring  a period of past prevalence, 
and H ong Kong antigens were recycled in 
the pandem ic of 1969. T h e  significance of 
these findings will be discussed.
48
notes
N. Masurel; Leiden, T h e Netherlands
Session I I
Interpretation of Antibody Patterns of Man: II. In  Europe
by
Analyses of strains of influenza A in m an 
and  anim als suggest th a t viruses derived 
from anim al sources have played an im ­
p o rtan t role in hum an epidemics. T h e  
presence of antibody against such an ' i n ­
fluenza A strain  in sera of persons in  a cer­
ta in  age group may indicate th a t this virus, 
o r a related  influenza strain , has caused 
previous epidemics in man.
Results of virologic and  serologic investi­
gations perm it the following conclusions 
and suggestions:
1. T h ere  is strong evidence th a t the an ­
tigen of influenza A /S w in e/1 930 is identical 
or related to the influenza strain  th a t caused 
the pandem ic of 1918-1919. From  1933 un til 
1957 all hum an A strains showed a distinct 
antigenic relationship  to the A /Sw ine/1930 
virus.
2. I t is highly probable th a t the antigen 
of the pandem ic A2 influenza virus strain 
of 1957 is identical or closely related  to the 
virus responsible for a pandem ic in 1889- 
1890.
3. T h e  A /E quine-2 /63  virus dem onstrates 
an antigenic relationship  w ith the hum an 
A2 strains in the an tibody  response to 
vaccination and in infection and re-infec­
tion experim ents in m an and ferrets. How­
ever, no relationship  was found in the cross 
haem agglutination-inhibition  test. A ntibody 
against the equine strain  has been found in 
m an in age groups which suggest th a t the 
A /E quine-2  virus or an  A /Equine-2-like 
virus may have caused epidemics in m an 
around 1900, th a t is, 10 years a fter the A2 
pandem ic of 1889-1890.
4.a). Four different experim ents (the 
cross H I test, the antibody response to 
vaccination and infection, and  the re ­
infection experim ents in  ferrets) dem on­
strate an antigenic relationship  between the 
H ong Kong virus and the A2 viruses and 
between the H ong Kong strain  and the A / 
Equine-2 viruses.
b). Exposure to A2 influenza viruses d u r ­
ing the period 1957-1967 increased the level 
and frequency of antibody titres against the 
A /E quine-2  virus in sera from older age 
groups.
c). T h e  pa tte rn  of antibody against the 
H ong Kong virus in sera collected before 
the 1957 pandem ic of A2 influenza suggests 
th a t a virus resem bling the H ong Kong/68 
strain  was prevalent in m an around  the 
beginning of this century, o r about 10 




Hideo Fukumi; Tokyo, Japan
Interpretation of Antibody Patterns of Man: III. In  Japan
by
Sera from residents in old people’s homes 
were exam ined for their antibody patterns 
by using five strains of type A influenza 
virus: A /Sw ine/30, A O /P R /8 /3 4 , A l /  
O hm achi/1 /53 , A 2 /K u m am o to /l/6 7 , and 
A 2 /A ich i/2 /6 8  (Hong Kong variant), in the 
hem agglutination-inhibition  test. T h e  sera 
were collected p rio r to the occurrence of 
H ong Kong influenza in Japan . T h e  fre­
quency distribu tion  of the antibody titers 
against each of these antigens is m ore or less 
characteristic for each, b u t the most char­
acteristic of them  is th a t for H ong Kong 
virus. As previously shown by many 
workers, the prevalence of H ong Kong an ti­
body in the general population  p rio r to the 
H ong Kong influenza epidem ic was rel­
atively low; only a small percentage pos­
sessed the H ong Kong antibody, mostly in 
a  tite r of 1:32 or, a t most, 1:64. However, in 
people over 70, the frequency of antibody 
titers against H ong Kong type virus was 
fairly high, and  it was even greater in 
people over 80. N ot only was the frequency 
of H ong Kong antibody fairly high, b u t the 
average H I tite r was considerably elevated, 
and in some individuals, it was as h igh as 
1:256 to 1:512.
I t  was also found th a t though H ong Kong 
antibody tite r was definitely correlated w ith 
the old A2 virus antibody tite r in younger 
people, there was no correlation between 
these titers in people over 70. For exam ple, 
in the old people, the frequency d is tri­
bution  of H ong Kong antibody tite r was 
found to be independent of their A2 a n ti­
body titers, whereas in younger people, this 
was not the case.
T hese findings suggest th a t about 70 years 
ago there was an era du ring  which the m ain 
antigen of type A influenza virus was the 
H ong Kong antigen independent from the 
m ain antigen of the old A2 virus. As for the 
worldwide epidem ic eras of influenza, some 
authors have suggested th a t influenza eras 
have been occurring successively from swine 
to AO, A l, and then A2, and  th a t now the 
era of H ong Kong influenza has ju st started. 
Previously, some D utch workers proposed 
th a t there had been an era abou t 80 years 
ago of an influenza virus whose m ain 
antigen was like th a t of the old A2 virus. 
H ere a fu rth er suggestion is m ade th a t im ­
m ediately following the early A2 era, which 





Interpretations of Antibody Patterns of Man:
Absorption of Hum an Sera with Hong Kong Variant, 
A/Equine-2, and Asian Influenza Viruses 
by
W illiam M. M arine and W ilton M. Workman; Atlanta, Georgia, U.S.A.
A ntigenic interrelationships am ong the 
H ong Kong varian t (HK), A /E quine-2  (Eq 
2), and Asian influenza A viruses were ex­
plored in sera obtained from nursing home 
and young ad u lt populations before and 
after the 1968-69 H ong Kong influenza 
epidem ic. A 2/H ong  K ong/8/68, A /E quine- 
2 /M ilfo rd /2 /6 3 , a n d  A 2 /Ja p a n /1 7 0 /6 2  
strains were used in m icrotiter hem aggluti- 
nation-inh ib ition  (HI) and antibody absorp­
tion techniques.
Persons in the nursing hom e population  
had b irthdates from 1869-1901. HK and 
Eq 2 antibodies, 85% and 20% respectively, 
were almost exclusively found in sera ob ­
tained in 1964 from the 118 persons born 
in the years 1869-1891 (pre-1892). T h e  prev­
alence of Asian antibody was high, regard­
less of age. HK vaccine in the pre-1892 
group caused a fivefold rise in HK antibody, 
a rise in Eq 2 in two-fifths of the group, and 
no rise in Japan /170  titer. In  71 young 
adults the pre-epidem ic prevalence of HK, 
Eq 2, and Japan /170  antibody was 3%, 0%, 
and 93%, respectively. HK vaccine produced 
a m oderate response in HK, no response to 
Eq 2, and a sixfold rise in Jap an /1 7 0  titer.
A ntibody absorption experim ents were 
perform ed on individual sera d ilu ted  to 
contain two H I antibody units. T h e  sera 
came from (A) the nursing hom e group in 
1964,(B) the nursing hom e pre-1892 group 
w ith ^  fourfold rise in HK antibodies 
after HK vaccine, (C) seven of the nursing 
home group w ith Eq 2 antibody rises to 
1:64 after HK vaccine, and (D) the young 
ad u lt group before and after == fourfold 
rise in HK antibodies after H K  vaccine.
HK virus consistently removed Eq 2 a n ti­
body from Groups A and C when the sera 
contained HK antibody (12/12 sera). Eq 2 
virus also removed HK antibody from 
G roups A and C when the sera contained 
Eq 2 antibody (15/16 sera); however, Eq
2 virus infrequently  removed HK antibody 
from sera in Groups A and D which had 
no Eq 2 tite r (4/16 sera).
W hen HK antibody was not present, 
HK virus removed Jap an /1 7 0  antibody oc­
casionally from sera in G roup A as well as 
from pre-vaccine sera in G roup D (8/29 
sera). Further, there was little  im prove­
m ent when HK antibody  was present in 
Groups A and B (13/30 sera). Japan /170  
virus removed HK antibody from Groups 
A and B at a com parable low frequency 
(10/28 sera). However, after use of HK 
vaccine in G roup D a striking im provem ent 
occurred in the absorption of Japan /170  
antibody w ith HK virus (9/9 sera) and in 
the absorption of HK antibody w ith J a p a n / 
170 virus (8/8 sera).
Eq 2 virus removed Japan /170  antibody 
poorly in sera from G roup A w ith or w ith ­
out Eq 2 antibody (0/10 and 2 /9  sera, re ­
spectively) as well as in G roup C (1/7 sera). 
Japan /170  virus partially  removed Eq 2 
antibody from Groups A and C (6/13 sera) 
bu t not to the same degree th a t H K  re ­
moved Eq 2 antibody from these same sera.
These studies suggest a close relationship 
between HK and Eq 2 strains. A m ore dis­
tan t relationship  is seen between HK and 
Asian strains in the nursing hom e sera; 
however, the dual response of a young adu lt 
group to HK vaccine confirmed by recipro­
cal antibody absorption supports a definite 
association between these strains. A differ­
en t sequence of exposure of the two groups 
to HK and Asian strains m ight explain the 
contrasting responses of the two groups to 
HK vaccine.
Both antibody prevalence and antibody 
absorption studies in these populations sup­
port the hypothesis th a t the HK virus is 
the best existing prototype of the hum an 
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by





Problems of Influenza Virus Vaccine Standardization 
by
Nicola M. Tauraso and Thomas C. O’Brien; Bethcsda, Maryland, U.S.A.
T h e  lack of reliable laboratory m ethods 
for determ ining the antigenicity  of inacti­
vated influenza virus vaccines prom pted 
o u r laboratory to reinvestigate the rep ro ­
ducibility  of the tests used for m easuring 
the antigenic content of influenza vaccines, 
namely, the CCA (chick cell agglutinating  
unit) and mouse potency tests.
T h e  data  obtained in the second p a rt of 
the mouse potency test, th a t is, the neu ­
tralization test perform ed either in the 
mouse or em bryonated egg, statistically 
dem onstrated protective differences between 
two vaccines differing in antigenic mass 
by as little  as twofold. However, the de­
pendence upon  a single egg or mouse neu­
tralization test to provide the correct 
vaccine/reference ratio  was based upon an 
assum ption rendered invalid by "biological” 
variation. Further, the test was long and 
tedious, and it would be im practical to 
perform  the num ber of tests needed to ob­
tain statistically significant results. T hus, 
the extrem e variability  observed between 
individual mouse potency tests and the im- 
practicality of perform ing this test in 
statistically sufficient num bers precluded its 
usefulness for m easuring the antigenic con­
ten t of inactivated influenza vaccines.
T h e  sim pler CCA test, on the o th er hand, 
d id provide the reproducibility  required  
for the correct determ ination  of the vaccine/ 
reference ratio  once a stable CCA refer­
ence vaccine was prepared. T h is test was 
easily reproducible, and results obtained 
were sufficient for draw ing a m eaningful 
and reliable conclusion about vaccine 
potency.
T h e  problems of m easuring the relative 
content of several com ponents in m ultiva- 
lent vaccine preparations and of finding a 
test which positively correlates w ith vac­
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Effect of Dosage and Route of Inoculation upon Antibody Responses to 
Inactivated Hong Kong Influenza Virus Vaccine in Man 
by
Nicola M. Tauraso, Frank A. Pedreira, and Rachel Yahwak; Bethesda, 
Maryland, U.S.A., and R ichard A. Gleckman, Morton A. Madoff, and 
Jacobo Sabbaj; Boston, Massachusetts, U.S.A.
In  1947 Van G elder et al showed th a t a 
0.1 ml in traderm al (ID) injection of inac­
tivated influenza vaccine was superior to
1.0 m l adm inistered by the subcutaneous 
(SC) route. From studies conducted 10 years 
la ter (Boger et al and M cCarroll et al), the 
opposite was concluded, th a t is, the sm aller 
ID dose offered no advantage or was in ­
ferior to the larger SC dose. I t is difficult 
to know w hether the data and conclusions 
of these earlier studies would be valid w ith 
the more po ten t vaccines available today. 
W ith  the advent of the 1968-69 H ong Kong 
influenza epidem ic it seemed w orthw hile to 
re-evaluate w hether a sm aller ID dose would 
elicit antibody responses com parable to 
those following the larger SC dose. T hree  
doses—0.1 ml (65 CCA), 0.25 m l (160 CCA), 
and 0.5 ml (320 CCA) of zonal-purified vac­
cine—were evaluated. T h e  0.1 m l dose was 
adm inistered by both the ID  and SC routes, 
and the o ther doses were given by the SC 
route only. T h e  effect of "booster” inocula­
tion by the same route 2 and 4 weeks la ter 
was also studied. Sera were exam ined by 
the hem agglutination-inhibition  test and 
the antibody response was determ ined by 
the percent showing fourfold or greater
tite r rises and by the increase in geometric 
m ean tite r  (GM T).
T h e  antibody response to the first inocu­
lation was highest in the 0.1 m l/ID  groups 
and the lowest in the 0.1 m l/SC  groups. 
T h e  responses in the 0.5 m l/SC  and 0.25 
m l/SC  groups were interm ediate, w ith the 
responses of the form er averaging the b e t­
ter of the two. All groups receiving a sec­
ond inoculation 2 weeks after the first ex­
perienced an increase in antibody response. 
Responses to the second inoculation given 4 
weeks after the first were variable. Consider­
ing the overall effect of all com binations of 
doses and routes, the ID groups appeared 
to achieve the best antibody response, the 
0.1 m l/SC  groups were least effective, and 
the 0.5 m l/SC  and 0.25 m l/SC  groups were 
interm ediate, w ith the form er appearing 
slightly better.
T h ere  appeared to be an inverse relation ­
ship between antibody response and p re ­
im m unization antibody titer.
O ur data  show th a t using vaccine of sim i­
lar CCA content, 0.1 ml intraderm ally, 
w ould be a reasonable, if not better, a lter­
native to the h igher 0.5 ml SC dose. T h e  




Antibody Responses to and Efficacy of 
Inactivated Influenza Vaccine 
by
Tadao Sonoguchi; Tokyo, Japan
In O ctober 1968 about 3,000 G round Self- 
Defense Force (GSDF) personnel in five 
camps were inoculated subcutaneously with 
various doses of m onovalent H ong Kong in ­
fluenza vaccine contain ing 300 chick cell 
agg lu tinating  units (CCA)/m l of the A 2/ 
A ich i/2 /68  virus.
T h e  paired  sera from half of the subjects 
obtained before and 1 m onth after the 
inoculation were exam ined for their hemag- 
g lu tina tion-inh ibition  (HI) antibody titers. 
T h e  frequency d istribu tion  of H I antibody 
titers in prevaccination sera was < 1 :16  in 
92%; 1:16 in 3.8%; 1:32 in 3.6%, and 1:64 
in 0.5% (H I titers are shown in final 
d ilution).
Percentages of the subjects possessing an 
H I antibody tite r of <1 :16 , and the 
geom etric mean of those H I titers of ^  1:16 
one m onth  following inoculation of various 
doses were: 40-50% and 1:30-1:50 for the 
groups given 0.2-0.25 ml in a single dose; 
7-50% and 1:45-1:84 for those given 0.5 ml 
in a single dose; 7-26% and 1:56-1:119 for 
those given 1.0 ml in a single dose, and 1- 
19% and 1:49-1:111 for those given 0.5 ml 
in two separate doses. In  one of the camps 
w here the antibody response was extremely 
high, it was serologically proven th a t there 
were m ore or less sporadic H ong Kong in ­
fluenza cases w ithin 1 m onth  after vacci­
nation.
An epidem ic due to H ong Kong virus oc­
curred  from January  through M arch 1969 
in a vaccinated camp of approxim ately
2,000 GSDF soldiers in Tokyo. In a un it 
consisting of 980 men of whom 90% were 
living on the post, 80% were vaccinated. 
T h e  infectivity rate  was 16% in the vac­
cinated group  (7% for the ones given 1.0 
ml, 13% for these given 0.5 ml, and 43%
for those receiving 0.2 ml), and it was 26% 
in the unvaccinated group, living in the 
same barracks w ith the vaccinated. T h e  rate 
in the control group living in another 
barrack was 63%. T h e  num ber of paired 
sera w ith fourfold rises in H I antibody titer 
to H ong Kong virus was 21 of 134. T he 
second serum specimen was taken 1 m onth 
after vaccination. Before the epidem ic, 20 of 
the 21 had an H I titer of =£1:32 and one 
had a titer of 1:64.
D uring the same period an epidem ic of 
Influenza B occurred in this camp, and the 
infectivity rate was 14% for the vaccinated 
group as well as for the control group. 
T herefore, exposure in the two groups was 
apparently  equal, indicating th a t differ­
ences in infectivity rates for H ong Kong 
virus between vaccinated and unvaccinated 
groups were due to the H ong Kong vaccine.
In  contrast to the aforem entioned findings 
on infectivity, there was no significant 
difference in incidence rate  between the two 
groups.
In ano ther u n it of about 1,200 men, half 
of them living in the camp, about one-third 
were inoculated w ith two doses of com­
mercial vaccine containing 200CCA/ml of 
H ong Kong virus and lOOCCA/ml of a B 
strain  given in a single dose of 0.3 ml. 
T h ere  was no difference in the infectivity 
rate between the vaccinated and unvac­
cinated individuals. T h e  inability  to detect 
a vaccine effect in this group was ascribed 
to the relatively small num ber of subjects 
living in the camp. T h e  infectivity rate of 
those not vaccinated who lived in the camp 
was 37%, whereas th a t of those, also not 




Studies with Inactivated Influenza Vaccines Purified by Zonal Centrifugation: I. Adverse 
Reactions and Serologic Responses 
by
S. R. Mostow; Cleveland, Ohio, U.S.A., S. C. Schoenbaum; Boston, Massachusetts, U.S.A., 
W. R. Dowdle, M. T . Coleman, and H. S. Kaye; Atlanta, Georgia, U.S.A.
Session III
High (3000 CCA unit) and standard  low 
(300 CCA unit) doses of form alin inacti­
vated influenza vaccines purified by zonal 
u ltracen trifugation  were evaluated in a 
double-blind m anner for adverse reactions 
and antibody responses in three po p u la­
tions. M onovalent A 2 /Jap an /17 0 /6 2  and 
A 2 /A ich i/2 /68  vaccines a t both dosage 
levels were adm inistered to volunteers 
am ong residents of a retirem ent com munity, 
students in ju n io r and senior high schools, 
and inm ates a t the Georgia State Prison. 
T h e  la tte r two populations were also given 
high and low doses of h ighly purified B / 
M assachusetts/3/66 vaccines as controls. 
Commercially available Sharpies centrifuged 
bivalent and polyvalent vaccines containing 
the 1967-68 form ulation were included as 
add itional controls in the two ad u lt po p u ­
lations. All vaccines were adm inistered sub- 
cutaneously in 1 ml volumes by je t injector 
gun. Sera were collected before and 3 weeks 
after im m unization.
Local and systemic reactions were fewest 
w ith the low doses of all three purified 
vaccines. T h e  high doses of A 2 /Japan  and 
A 2/A ichi vaccines produced a two- to 
threefold greater incidence of adverse re ­
actions. Nevertheless, the percentage of ad ­
verse reactions produced by the high doses 
did not exceed and was generally less than 
th a t observed w ith the commercial vaccines 
in the two ad u lt populations w here both 
zonal centrifuged and Sharpies centrifuged 
vaccines were used. Unlike the high doses 
of the A2 vaccines, 3000 CCA units of B / 
Massachusetts adm inistered to prison vol­
unteers produced more frequent and more
severe systemic reactions than the polyva­
lent vaccine. T h e  same 3000 CCA units of 
B /M assachusetts caused very severe systemic 
reactions in the school populations and re ­
sulted in a sharp increase of absenteeism. 
T h e  reasons for the high toxicity of B / 
Massachusetts vaccines have no t been fully 
evaluated. Adverse reactions to all vaccines 
were more frequent in the school-age po p u ­
lation.
T h e  A 2/Japan  vaccines and the com m er­
cial vaccines stim ulated m oderate to high 
geom etric mean titers by hem agglutination- 
inhibition  tests against the homologous 
A 2 /Japan  antigen. However, these vaccines 
d id  not stim ulate a significant antibody 
response to A 2/A ichi/2/68 or to o ther 
H ong Kong variants. T h e  homologous 
serum antibody response to the Aichi vac­
cines was excellent in all three populations; 
nearly 80% receiving the low dose showed 
a fourfold or greater increase in antibody 
titer and over 90% of those receiving the 
high dose had a fourfold o r greater re­
sponse. A 2/A ichi vaccines in the two adu lt 
populations produced A 2/Japan  titers equal 
to or greater than th a t produced by the 
A 2/Japan  vaccines. T h e  high doses of all 
three vaccine strains produced geom etric 
mean titers two to three times greater than 
those produced by standard  doses.
T h u s it was dem onstrated th a t high doses 
of purified influenza vaccines could be 
given safely, th a t purification n either en ­
hanced nor decreased antigenicity, and th a t 
tenfold greater doses of vaccine produced 




Studies with Inactivated Influenza Vaccines Purified by Zonal Centrifugation:
II. Efficacy
S. C. Schoenbaum; Boston, Massachusetts, U.S.A., S. R. Mostow; Cleveland, Ohio, U.S.A., 
W. R. Dowdle, M. T . Coleman, and H. S. Kaye; Atlanta, Georgia, U.S.A.
Session III
H igh (3000 CCA unit) and standard  low 
(300 CCA unit) doses of m onovalent purified 
vaccines described in P art I were evaluated 
in a double-blind m anner in two adu lt 
populations for protective effectiveness 
against illness caused by the H ong Kong 
influenza virus. A sharp  influenza outbreak 
of 3 weeks’ du ra tion , w ith an overall clinical 
attack rate of approxim ately 40%, occurred 
in late Decem ber 1968 am ong the inm ates 
of the Georgia State Prison. A sm aller o u t­
break beginning in late December, lasting 
5 to 6 weeks, w ith an overall clinical attack 
rate of approxim ately 10% occurred am ong 
the residents of the re tirem ent community. 
Epidemics in both populations occurred 4 
to 6 weeks a fter single injections of vaccine 
were given. No epidemics occurred in the 
school-age population .
T h e  attack rates am ong recipients of low 
or high doses of A 2 /Japan  vaccines in the 
prison were virtually  identical to those of 
the B/M assachusetts control groups. T he 
attack rate am ong those receiving the 3000
CCA units Aichi vaccine was nearly 70% 
less than  the rate for the A 2 /Japan  or 
B/M assachusetts vaccine groups. A lthough 
no m onovalent influenza B vaccine was 
given to the residents of the retirem ent 
com munity, a sim ilar 60-70% reduction in 
attack rate was observed am ong the  3000 
CCA u n it Aichi recipients when compared 
to the A 2/Japan  vaccine recipients.
Furtherm ore, in the high Aichi groups in 
both populations, those who became ill 
tended to have less m orbidity, fewer and 
lower fevers, and shorter stays in bed. T he 
attack rates am ong the groups receiving the 
low doses of Aichi vaccine were somewhat 
less than the rates am ong those receiving 
the A 2 /Japan  or B /M assachusetts vaccines, 
bu t the effect was not statistically significant 
in either population. T h e  bivalent and 
polyvalent commercial vaccines were also 
w ithout protective effect; and, in fact, in 
both populations the polyvalent vaccine 





Effect of Vaccination of a School-Age Population 
Upon the Course of an A2/Hong Kong Influenza Epidemic
by
A. S. Monto, F. M. Davenport, J. A. Napier, and T . Francis, Jr.; Ann Arbor,
Michigan, U.S.A.
In  influenza outbreaks, the greatest m or­
bidity is experienced by children of school 
age. These children are also responsible in 
great p a rt for the dissem ination of the virus 
through the com m unity. Vaccination of 
school children should, therefore, decrease 
m orbidity in the most susceptible segment 
of the population  and also curtail trans­
mission to the adults and younger children.
T o  control the anticipated  outbreak of 
influenza in the w inter of 1968-1969, Hong 
Kong varian t influenza vaccine was offered 
to the school children of Tecum seh, M ichi­
gan, a com m unity which has been under 
study since 1959. More than 85% of the 
school children were vaccinated subcutane- 
ously w ith 0.5 ml of a zonal ultracentrifuge- 
purified preparation  of inactivated A 2/ 
A ichi/2/68 (800 CCA per ml). Systemic 
reactions to the vaccine were rare. Pre- and 
post-vaccination blood specimens were ob ­
tained from approxim ately 5% of those 
inoculated, and 92.4% exhibited a fourfold 
or greater rise in  H I titer.
Surveillance of respiratory disease had 
been underway in Tecum seh since 1965. 
A group of families was contacted weekly 
and the illnesses occurring in the past week 
were recorded. Specimens for m icrobial 
isolation were also collected when illnesses 
were reported. T h e  city of A drian, M ichi­
gan, 12 miles from Tecum seh, also had a 
surveillance program  underway, using the 
same questions on respiratory disease in a 
somewhat different form at. A drian, there­
fore, appeared to be a suitable comparison 
com m unity against which to measure the 
effectiveness of the vaccination program  in 
Tecum seh.
T h e  first isolation of H ong Kong variant 
influenza virus was m ade in Tecum seh 2 
weeks after the period of vaccination. I t 
continued to be isolated in both  Tecum seh 
and Adrian for 9 additional weeks. 
T hrough  this 10-week-period, m ean rates 
of illness, adjusted for differences in p re ­
epidem ic reporting, were 2.8 times h igher 
than in Tecum seh. School absenteeism in 
Tecum seh did not exceed pre-established 
threshold levels, whereas it was m arkedly 
increased in A drian. T h e  protection from 
illness was not lim ited to the school chil­
dren; illness rates in Tecum seh were also 
lower for adults and younger children. So 
many individuals in the school-age group 
were vaccinated th a t protection even ex­
tended to those few who were not vacci­
nated. T h e  rates of illness in Tecum seh 
were shown to be m arkedly lower than  those 
in two o ther M ichigan cities w here sim ilar 




An Evaluation of Influenza Immunization:
Influence of Route of Administration and Vaccine Strain 
by
R obert H. W aldman and Parker A. Small, Jr.; Gainesville, Florida, U.S.A.,
James O. Bond, Eldert C. Hartwig, E. Charlton Prather, and Robert L. Baratta; 
Jacksonville, Florida, U.S.A., Lawrence P. Levitt and John S. Neill; Tam pa, Florida, U.S.A.
A pproxim ately 2,000 school teachers from 
the T am pa, Florida, school system volun­
teered to partic ipate in a study designed 
prim arily  to assess th ree variables in in ­
fluenza im m unization: 1) rou te of adm inis­
tration: aerosol vs. injection, 2) strain  of 
virus used in vaccine: b ivalent (A2 and B) 
vs. A 2/H ong Kong, and 3) num ber of 
doses: one vs. two. T h e  experim ental groups 
were as follows:
First Second
Study Volunteers (December 12-13, 1969) (January 3, 1969)
G roup Per G roup Injection Aerosol Injection Aerosol
1 235 H S H S
2 230 H S S S
3 231 B S B S
4 240 B S S S
5 240 S H S H
6 239 s H s S
7 237 s B s B8 234 S B s S9 237 s S s S
S — saline; B =  b ivalent vaccine; H  =  A 2/H ong  Kong m onovalent vaccine.
Each person, therefore, received in a double­
b lind  m anner both  an injection and an 
aerosol adm inistra tion  on two occasions
3 weeks apart. A pproxim ately half of the 
study population  gave two or three blood 
and two nasal wash specimens. A brief 
history, including smoking habits, was ob ­
tained. Each teacher then kept a daily 
record of symptoms for the next 11 weeks. 
Shortly after the in itia l im m unization, an 
influenza epidem ic occurred, as shown by
isolations of A 2/H ong  Kong virus, a n ti­
body rises, and increased absenteeism in 
the local industries and schools.
Over 2.5 m illion pieces of data  were col­
lected. Com puter program s were developed 
to determ ine illness rates defined in a va­
riety of ways, side effects associated w ith the 
different vaccines and their modes of ad ­
m inistration , and correlations between 
smoking habits and illness rates. Infection 




Antibody Responses to and Efficacy of 
Inactivated Spray Vaccines 
by
A. S. Beare; Salisbury, England
V olunteers were sprayed intranasally  w ith 
killed influenza B vaccine and  the extent of 
their protection assessed by means of a de­
liberate challenge w ith living, homologous 
virus.
Two types of trials were perform ed. In 
the first of these, 19 volunteers sprayed 
themselves intranasally on e ith er one or 
two occasions w ith 1.0 ml of vaccine con­
ta in ing 5,500 haem agglutinating  un its by 
means of a coarse hand  spray. A control 
group of 10 received phosphate-buffered 
saline by the same m ethod. All the vol­
unteers were subsequently adm itted  to the 
Common Cold Research U n it and chal­
lenged w ith 100,000 egg-infecting doses of 
the virus used in the p reparation  of the 
vaccine. Infections were assessed from the 
incidence of clinical reactions, isolations of 
virus from nasal washings taken on the 
second, th ird , and fourth  days after the 
challenge and from serum  antibody rises 
2-3 weeks later. No reduction  of infections 
occurred in the vaccinated volunteers as 
compared w ith those in the controls.
In  the second trial series, the protective 
effects of intranasal spray of inactivated 
influenza B vaccine were com pared w ith 
those of conventional vaccines. G roups of
about 20 factory workers were allocated at 
random  to each of the following vaccine 
groups, (1) aqueous paren tera l influenza 
B vaccine, (2) sp lit paren tera l influenza B 
vaccine, (3) intranasal killed influenza B 
vaccine given twice in the same dose as 
before by means of a fine hand  spray, and 
(4) a heterologous paren tera l influenza A 
vaccine, which served as an  unprotected  
control. All the volunteers were la ter chal­
lenged w ith 10,000 egg-infecting doses of 
live virus of the k ind used in the p rep ara­
tion of the first three vaccines. Infections 
were diagnosed by rises of serum antibody
2 weeks later. W hile the control group 
showed the expected incidence of infec­
tions and the two paren teral vaccine groups 
showed appreciable degrees of protection, 
the protective effect seen in the group re ­
ceiving in tranasal spray was apparently  
negligible. I t is possible, however, th a t the 
vaccine was not wholly inert.
No estim ations were m ade of local a n ti­
body form ation after the in tranasal vaccina­
tions.
W hether killed intranasal vaccines are 
potentially  able to protect against influenza 
B is not known, b u t in the doses used in 
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Antibody Response to and Efficacy of Live Virus Vaccines 
by
D. A. J. Tyrrell and A. S. Beare; Salisbury, England
Live influenza virus vaccination has po­
tential advantages and disadvantages com­
pared w ith killed virus vaccine given by 
intram uscular injection. A sm aller quantity  
of live virus would be needed to vaccinate 
each individual bu t, if the virus were very 
attenuated , a large dose m ight be needed 
to infect, and, in addition, some activity 
m ight be lost in freeze-drying the virus. 
Nevertheless, live virus vaccination is more 
likely than any o ther m ethod to stim ulate 
antibody in the respiratory mucosa. An 
im portan t difficulty is th a t there is no 
agreed m ethod for regularly inducing the 
attenuation , nor are there laboratory 
" m arkers” to indicate th a t the attenuation  
has occurred. These would be essential if 
live virus vaccination were to be used in 
the face of an epidemic. Some attenuation  
probably takes place in the first few pass­
ages, b u t it is not enough to make the 
viruses suitable as vaccine strains.
W e have therefore tried  to a ttenuate 
completely influenza A2 and B strains by 
up to 30 serial passages in the allantoic 
cavity of eggs a t 33°. No attenuation  oc­
curred. W e have recently tried the m ethod 
of passing viruses in the presence of an
increasing concentration of horse serum, 
thus selecting inhibitor-resistant variants. 
Serial passage was shown to induce an in ­
creasing degree of inh ib ito r resistance in 
the virus and an increasing degree of a t­
tenuation  for volunteers. T his was ob ­
served w ith both an Asian strain  and a 
H ong Kong strain.
T h e  H ong Kong virus was also passed 
serially a t 25° in eggs, b u t it did not seem 
m uch fu rther attenuated  as a result; how­
ever, a virus strain  supplied by D r. Maassab 
with a much higher degree of adaptation  
to low tem perature is now being tested, and 
the results will be reported a t the confer­
ence.
Partly or completely attenuated  strains 
have been used to induce or detect protec­
tion. Influenza B strains gave partia l p ro ­
tection after one dose and almost complete 
protection after two doses, and protection 
persisted for 7 months. A com parative study 
showed that there was protection after vac­
cination with killed virus by the parenteral 
route and with live virus by the nasal route.
T h e  relative susceptibility and efficiency 
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L aboratory  Characteristics of A ttenuated  Strains of Influenza Virus
by
H u en in  F. Maassab; Ann A rbor, M ichigan, U.S.A.
A ttenuation  of influenza virus p rio r to
1967 was achieved by gradually  lowering 
the incubation  tem pera ture  u n til optim al 
grow th, a t 25°C, was obtained.
T h e  process of a ttenuation  of a H ong 
Kong strain  was m odified and shortened 
considerably. T h e  tem pera tu re  of incuba­
tion was changed ab rup tly  from 35°C to 
25 “C, w ith selection of a cold varian t 
by the p laque assay system.
A set of genetic m arkers for the cold 
varian t was developed for assessing the po ­
ten tial virulence of cold-passaged lines. T h e  
cold v a rian t of the  H ong Kong strain  was 
tem pera ture  sensitive and acid labile and 
produced a small-sized p laque in  prim ary 
chick kidney cells incubated a t 35°C. A ddi­
tional d ifferentiating  biological properties 
re la ting  the adap tion  of the virus to growth 
a t 25° to loss of virulence in  a suscepti­
ble host will be presented.
T h e  cold-adapted line was found to be 
relatively av iru len t and highly antigenic
for mice and ferrets. V irus was recovered 
from the nasopharynx of infected ferrets 
du ring  the first 3 days. T h e  virus recovered 
still had  the im paired capacity to grow a t 
41 °C (rct/41-), was sensitive to acid pH , 
and produced small plaques a t 35°C and 
larger ones a t 25°C.
After a series of p laque purifications, the 
cold varian t showed fu rth e r loss of v iru ­
lence to mice, m ore vigorous growth a t 25°C, 
complete failure of reproduction  a t 41 °C, 
and good antigenic potency.
M arkers of the p laque-purified cold vari­
an t were stable a fte r a t least 10 consecutive 
passages in e ither tissue cu ltu re  a t 35°C or 
in mice.
Cold variants of type B influenza virus 
have a narrow er range of tem peratu re  sen­
sitivity com pared to type A strains. A tten u ­
ated B strains showed an im paired plaqu- 
ing efficiency and reproductive capacity at 
35°C (rct/35-) when com pared to the type 
A strains a t 41 °C.
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L aboratory Characteristics of A ttenuated  Influenza Virus Strains
by
A. S. Beare; Salisbury, E ngland
Session IV
Difficulties in  p reparing  satisfactory live 
influenza vaccines are allegedly due to ge­
netic instability  of the viruses. I t  has long 
been said th a t sim ple passage in an alien 
host will rapidly  abolish th e ir pathogenicity  
for m an, and ra th e r less rapidly, th e ir h u ­
m an infectivity and antigenicity. Host- 
derived m aterial associated w ith the hae- 
m agglutinins can usually be detected in 
viruses passed in em bryonated hens’ eggs, 
b u t no o th er m ajor changes have been re ­
ported. So far, however, the host compo­
nents have no t been shown to possess any 
biological activity. One influenza A virus 
and two influenza B viruses w ith different 
grow th characteristics were passed re ­
peatedly  in eggs in an effort to produce 
a tten u ated  m utants. A lthough m inim al 
changes were a t first induced, there  were 
no obvious differences in the hum an p a th ­
ogenicity and infectivity of early and late 
passes of the viruses when these were given 
to volunteers of com parable susceptibility 
to infection a t the Common Cold Research 
U nit. N or could a ttenuation  be hastened 
by passing one of the  viruses repeatedly at 
low dilutions. In trials previously re ­
ported, the effects of virus inoculations 
were assessed from virus excretions, inci­
dence of clinical reactions, and rises of cir­
culating  antibody, and it was clear that 
pathogenicity and infectivity for m an are 
relatively stable characteristics of influenza 
viruses when these are propagated in the 
laboratory a t nearly optim al tem peratures.
Experim ents were then perform ed w ith a 
virus known as A 2/E ngland/501/68, which 
is antigenically sim ilar to A 2 /T okyo /3 /67 ,
and w ith the strain  A 2 /H ong  K ong/1/68. 
By passing the form er in eggs in the pres­
ence of heated horse serum , it was possible 
to ob tain  a virus totally resistant to serum  
inh ibitor. W hen this virus was com pared 
w ith the paren t virus in the same volunteer 
tria l, it was clearly m uch a tten u ated  a l­
though it rem ained infective and antigenic. 
C om parable success was not, however, 
achieved w ith A 2/K ong K ong/1 /68 . Most 
of the sensitivity to in h ib ito r was abol­
ished by prolonged passage in the presence 
of horse serum , and the  virus was ap p re ­
ciably a ttenuated , b u t the little  sensitivity 
which rem ained was apparen tly  associated 
w ith hum an pathogenicity. As in the case 
of A 2 /E n g lan d /5 0 I/6 8 , the modified viruses 
were infective and antigenic.
T h e  inhibitor-sensitive strain  of A 2/ 
H ong K ong/1/68 was also a tten u ated  by 
serial passages in em bryonated eggs a t 25°C. 
Virus titres were, however, low, and it was 
necessary to propagate the viruses a t lim it 
d ilu tion  a t 33°C before they could be used 
in volunteer trials. I t  is no t yet clear 
w hether su itable degrees of a ttenuation  and 
infectivity can be achieved sim ultaneously, 
and there  is no inform ation on the stability  
of the low tem perature  m utants.
W hen wild and a ttenuated  viruses were 
exam ined in the  laboratory, the inhibitor- 
resistant viruses eluted m ore rapidly  from 
red blood cells than  the inhibitor-sensitive 
viruses. T h is is a well known characteristic 
of inhib itor-resistant viruses and is p ro b ­
ably not a m arker of a ttenuation . Studies 
on the characters of the a ttenuated  influ­




Evaluation of Influenza Virus M utants for Use in Live Virus Vaccine
by
Jo h n  M ills V, Jo h n  VanKirk, and  R obert M. Chanock; Bethesda, M aryland, U.S.A.
A safe, im m unogenic live a ttenuated  in ­
fluenza virus vaccine w ould possess a n u m ­
ber of theoretical advantages over inacti­
vated vaccines for the im m unoprophylaxis 
of influenzal disease. Chief am ong these 
are m ore effective stim ulation  of protective 
local respiratory secretory antibody and 
greater ease of adm inistration . A t present, 
an acceptable live influenza virus vaccine 
is not available; however, several recent de­
velopm ents suggest th a t this goal m ay be 
w ith in  sight.
A daptation  to grow th a t abnorm ally low 
tem peratures has resulted in the emergence 
of a ttenuated  m utan ts of poliovirus, resp ira­
tory syncytial virus, measles virus, and 
o th er viruses. Similarly, Dr. Maassab has 
shown th a t growth of influenza A virus in 
eggs a t low tem perature  (25°C) results in a 
loss of viral virulence for mice. Stim ulated 
by these observations, we investigated the 
infectivity and virulence of H ong Kong 
influenza A2 which had been propagated 
and term inally  d ilu ted  a t 25°C in bovine 
kidney (BK) tissue culture. W hen lO T C D ^ 
of this 25°C grown virus (BK passage 13) 
was given to eight serum  neutralizing  a n ti­
body free volunteers, we were unable to 
recover virus from these m en, no r did ill­
ness develop; however, three volunteers de­
veloped a low level rise in serum  antibody. 
A nother group of eight seronegative vol­
unteers exhibited  a sim ilar response to 
10f,T C D co of virus. In  contrast, when 
IO T C D jo was adm inistered to eight a n ti­
body free men, each m an shed virus, six 
men developed influenza] disease (five with 
fever), and antibody responses were more 
m arked than  those seen previously. In
this circumstance, it appeared th a t p ro p a­
gation at low tem perature  had led to the 
emergence of a m u tan t w ith decreased in ­
fectivity for m an. U nfortunately , when a 
m oderate level of infection d id  occur, it 
was associated w ith influenzal symptoms. 
Because of this failure to dissociate v iru ­
lence from infection, we have tu rned  our 
a tten tion  to ano ther approach to a tten u a ­
tion of influenza A virus.
T h e  newest approach involves the selec­
tion of conditional lethal, tem perature- 
sensitive (ts) m utan ts of influenza A virus. 
W ith o ther respiratory viruses and myco­
plasma, workers in o u r laboratory  have 
shown that certain ts m utations are asso­
ciated with a ttenuation . In  part, this re­
sults from the m arked growth restriction 
exhibited  by such m utan ts a t 37°C (the 
tem perature  of the lower respiratory tract); 
at 32°-33°C (the tem perature  of the naso­
pharynx) these m utan ts grow in an u n ­
restricted fashion. W e succeeded in  isolat­
ing two ts m utan ts from BK influenza A2 
virus which had been grown in the  pres­
ence of 5-fluorauracil, a p o ten t chemical 
m utagen. One of the influenza A2 ts m u ­
tants exhibited m arked restriction of p laque 
form ation a t 37°C, whereas the o th er m u ­
tan t was restricted a t 38°C and above. In 
contrast, the wild type (parent) virus ex­
h ib ited  a high efficiency of p laque form a­
tion a t 39°C. P relim inary com plim entation 
studies suggest th a t the two m utan ts were 
affected in different cistrons. T h e  behavior 
of the two m utan ts is being studied in 
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Session V
A djuvant Vaccines 
by
Charles H . Stuart-H arris; Sheffield, England
E nhancem ent of the an tibody  response 
to injected antigens by incorporation  of the 
la tter in an oily em ulsion has a respectable 
background of experience. T h e  use of em ul­
sified inactivated influenza virus vaccines 
has now been pursued for 18 years. T h e  
goal of enhanced serological response p e r­
sisting for 2 o r m ore years has been 
a tta ined . T h e  safety of the m ethod in re la ­
tion to im m ediate pyrogenic reactions has 
been dem onstrated and no carcinogenic 
effects are known to have occurred in m an. 
T h e  problem  of delayed local reactions 
after the injection of m ineral oil vaccines 
has not, however, been solved. B ritish ex­
perience of adverse reactions to commercial 
ad juvant influenza vaccine will be quoted.
New m ethods for ob tain ing  ad juvan t ac­
tion w ithout the risk of local abscess form a­
tion are needed both for inactivated whole 
virus and for split haem agglutinin vaccines. 
The peanu t oil A65 emulsion of W oodhour 
et al. (1964) is one solution, b u t experience 
in Britain with this m aterial is lim ited. T h e  
suggestion of a reversal of the ordinary 
water-in-m ineral oil emulsion to an oil-in-
w ater emulsion m ade by H erbert (1965) has 
the advantage of reducing the viscosity and 
perm itting  diffusion of the depot injection. 
A serological trial in Britain in 1966 by 
T aylor and others (1969) has shown equally 
good ad juvan t properties of the reversed 
em ulsion incorporating influenza virus vac­
cine so far as serological response is con­
cerned. T h e  results will be described. T oo 
few persons have yet received the m aterial 
for adequate  evaluation of the  likelihood 
of delayed local reactions. Even with the 
commercial m ineral oil em ulsion vaccine, 
the frequency of these has been of the 
order of 1:5000 to 1:10,000 of inoculated 
persons. Lack of the ability to reproduce 
such reactions in experim ental anim als 
ham pers developments.
H erbert, W. ]., (1965). Lancet, 2, p. 771. 
Taylor, P. ]., M iller, C. I.., Pollock, T . M., 
Perkins, F. T ., and W estwood, M . A., (1969). 
./. Hygiene (Camb.). In press.
W oodliour, A. F., Metzgar, D. P., S tim , T .
B., Tytell, A. A ., and H illem an, M. R ., 
(1964). Proc. Soc. Exp. Biol., 116, pp . 516-523.
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T h e  R ole of Early A lert and  A djuvant in  the  C ontrol of 
H ong Kong Influenza by Vaccines 
by
M aurice R . H illem an; W est Point, Pennsylvania, U.S.A.
Session V
Aqueous influenza vaccine m ay be qu ite  
effective in the control of the disease. T h e  
m inor antigenic variations in the virus 
which occur du rin g  the interpandem ic 
periods can usually be handled  adequately 
by periodic revision of the strain  form ula 
for the vaccine. However, the m ajor a n ti­
genic change in influenza A virus which 
occurs a t approxim ately 10-year pandem ic 
intervals precludes the usefulness of the p re ­
vious form ula vaccine and taxes the inge­
nu ity  of those who w ould hope to control 
pandem ic influenza by vaccines.
T h ere  are two principal approaches to 
the solution of this predictable and con­
tinu ing  dilem m a. One is to detect the em er­
gence of a new varian t in one p a rt of the 
world as far as possible in advance of its 
general spread in o rder to produce as much 
vaccine as possible and to carry ou t a vac­
cination program . T h e  o th er is to improve 
the u tility  of the old form ula prepandem ic 
vaccine to afford at least some degree of p ro ­
tection against the new strain  before its 
m ajor pandem ic spread. Both of these ap ­
proaches were p u t to test in the 1968 Hong 
Kong influenza pandem ic.
Vaccine preparation. T h e  first alert to 
o u r laboratories of the existence of the new 
H ong Kong influenza virus came in a letter, 
sent on August 16, 1968, from the  W orld 
H ealth  O rganization in Geneva. By Septem ­
ber 13, new facilities were being readied 
for vaccine production , and actual produc­
tion began in o u r laboratories on Septem ­
ber 23. T h e  problem  of low yield of virus 
in em bryonated hens’ eggs from the new 
strain  was solved by Dr. H. Fulcumi who 
furnished a well-adapted, high yielding 
H ong Kong influenza strain. T h e  first lot 
of vaccine m ade in o u r laboratories was 
released on Novem ber 19 and 6,167,000 
doses were released by the end of 1968. A 
total of 9,750,000 doses were released by 
Jan u ary  20, 1969. A total of 21,900,000 
doses were produced by all vaccine m an u ­
facturers in the U nited  States combined. 
M eantim e, the pandem ic itself had p ro ­
gressed rapidly  in the population  and had 
largely spent itself by the end of 1968. 
Hence, for the vast m ajority  of persons in 
the U nited  States, the new H ong Kong 
influenza vaccine was too little  and too late. 
T h is perform ance, in spite of heroics, was 
far less spectacular than  in the 1957 Asian 
influenza pandem ic in which there  was a 
5-m onth a lert p rio r to the pandem ic event 
in contrast w ith the short 3-m onth a le rt in 
the H ong Kong influenza pandem ic. Vac­
cine prepared  too late  for use in the U nited 
States was, however, in good tim e for use 
in the southern  hem isphere, where the 
seasons are opposite to those in the U nited  
States, and in certain  parts of E urope in 
which the m ajor event was delayed.
A d ju va n t 65 vaccine. One m eans for im ­
proving the perform ance of influenza vac­
cine is by incorporating  the  aqueous m a­
terial in to  an adjuvant. Studies were m ade 
by our group in m an of 1967 form ula in ­
fluenza vaccine in m etabolizable emulsified 
pean u t oil ad juvant 65. I t  was previously 
shown th a t incorporation  of aqueous vac­
cine into the ad juvan t increased the a n ti­
body tite r response in m an from fourfold 
to sixteenfold. T h is  same response was 
achieved w ith only V4 the antigen dose, or 
even less, m aking it possible to stretch the 
vaccine supply fourfold o r m ore in  time 
of u rgen t need. T h e  increased antibody 
effect afforded by the ad juvant may persist 
in m an for long periods—at least 6 years 
following the last previous dose of vaccine.
Im portan tly , incorporating the  influenza 
vaccine in adjuvant 65 effects a considerable 
broadening of antibody response in hum an 
beings against diverse influenza virus sero­
types. For exam ple, incorporating  aqueous 
1962 influenza A2 virus vaccine in adjuvant 
65 provided high level antibody response 
against the 1957 and the 1964 influenza A2 
variants, rendering these interpandem ic
96
changes in antigenic struc tu re  of the virus 
relatively u n im portan t from the im m uniza­
tion standpoint. An extrem e exam ple of 
broadening of antigenic response was 
shown for the recent H ong Kong influenza 
pandem ic virus in persons given old form ula 
vaccine in the adjuvant. Only 1.4% of pe r­
sons who received the  1967 form ula pre- 
Hong Kong influenza vaccine developed 
antibody against the 1968 H ong Kong virus. 
In  contrast, 55% of persons given the same 
vaccine in ad juvan t 65 responded. T h e  
antibody titers ranged from 1:10 to 1:160, 
and it seems reasonable th a t general ap p li­
cation in 1968 of the  old 1967 vaccine in 
ad juvant 65 m ight have afforded substantial 
protection against H ong Kong influenza in 
a significant portion  of the hum an  p o p u la ­
tion.
A nother m agnitude of antibody response 
enhancem ent to influenza vaccine in a d ju ­
vant 65 was recently dem onstrated in studies 
in which polynucleotides were added to the
adjuvant form ulation. T hese polynucleo­
tides, which also induce interferon, do en ­
hance antibody responses for a short period 
when given alone with aqueous antigen. 
Incorporation  of the polynucleotide in to  
ad juvan t 65 form ula influenza vaccine may 
give a fourfold-to-eightfold fu rth er increase 
in antibody, which is beyond th a t achieved 
by the ad juvan t alone. T h e  im plications of 
this synergistic hyperpo ten tia tion  of a n ti­
body response is obvious. T h e  activity of 
the polynucleotides in increasing antibody 
was separate and distinct from its capacity 
to induce interferon.
Influenza vaccine in ad juvan t 65 has been 
given to m ore than  16,000 persons w ithout 
untow ard effect. In  a recent follow-up of 
504 persons given ad juvan t 65 influenza 
vaccine in one to three  doses up  to 5 
years previously, only three, o r 0.6%, 




Influenza Im m unization: C linical Studies w ith Ether-Split Subunit Vaccines
by
F. B. B randon and I. W. M cLean, Jr.; D etroit, M ichigan, U.S.A.
Session V
T h e  clinical evaluation of ether-split 
T ype A2 influenza virus subun it (antigen) 
vaccines began shortly after 1957 when this 
virus first appeared. M onovalent, bivalent, 
and polyvalent antigen vaccines have been 
studied in infants, working age adults, and 
senior citizen groups. Because the specific 
strain  of A2 virus varied from year to year, 
in accord w ith recom m endations of the Divi­
sion of Biologies Standards, our experience 
includes the com plete spectrum  of T ype A2 
isolates from the earliest to the curren t 
Hong Kong virus. Generally, antigen vac­
cines were tested in parallel w ith conven­
tional vaccines contain ing  equal quantities 
of the same com ponents as their subunit 
counterparts. T h e  report summarizes our 
total serologic experience w ith the A2 virus, 
including recent studies w ith the  H ong 
Kong strain .
Pediatric  studies w ith the T ype A2 sub­
un it vaccines, showing th e ir im m unological 
effectiveness and pyrogen-free character in 
small children, have been reviewed in 
earlier publications. Sim ultaneously with 
these studies, serologic evaluation of these 
vaccines was started in an ad u lt population . 
T h e  pre-H ong Kong studies included 17 
pairs of conventional and antigen vaccines 
tested in  over 1,600 ad u lt volunteers. A n ti­
gen vaccines containing the H ong Kong 
virus were also studied in a hospital em ­
ployee group and in a senior citizen re tire ­
m ent comm unity.
Subjects received one dose of e ither a n ti­
gen or conventional vaccine and hem ag­
g lu tina tion  inh ib iting  (HI) antibody tite r 
was m easured in serum  samples taken a t the
tim e of and from 2 to 4 weeks following 
im m unization.
In  the studies conducted before 1968, 
1,671 subjects received one or ano ther of 
the 17 paired  vaccines. T h e  overall geo­
m etric m ean pre-vaccination H I antibody 
tite r against the A2 virus in this group was 
20.5. E ight hundred  and seventy-four vo lun­
teers were given conventional vaccine. 
These had a 3.5-fold increase in geometric 
m ean H I antibody tite r w ith a final titer 
of 72.6. T h e  747 antigen vaccinees displayed 
an eightfold increase in H I antibody w ith 
a final t ite r  of 163.5. Overall conversion 
rates in the two groups were 67 and 83%, 
respectively.
Tw o additional antigen vaccines con tain ­
ing the H ong Kong virus have been studied. 
T h e  first tria l com pared m onovalent a n ti­
gen and conventional vaccines in the  resi­
dents and employees of an East Coast re­
tirem ent com m unity. T h is study was started 
just before the H ong Kong epidem ic. T h e  
conventional and antigen vaccines were of 
equal im m unogenicity in both populations; 
however, resident serologic response greatly 
exceeded employee response, presum ably 
because of the form er g roup’s experience 
w ith a H ong Kong-like virus around  the 
tu rn  of the century. No influenza-like dis­
ease was seen in the com m unity du rin g  the 
epidem ic period.
T h e  second H ong Kong study was con­
ducted in a small group of hospital em ­
ployees approxim ately 2 m onths after the 
epidem ic peak. A fourfold increase in H I 





Desoxycholate Split Vacdnes 
by
M. F. W arburton ; Victoria, Australia
W ebster and Laver first showed th a t in ­
fluenza viruses d isrup ted  by trea tm en t with 
sodium  desoxycholate still re ta ined  most of 
th e ir antigenicity  for rabb its as well as 
their neuram inidase activity. W ith  the hope 
of developing a relatively non-toxic influ­
enza virus vaccine prelim inary  experim ents 
were conducted in bo th  children and adults 
using a desoxycholate split A 2/A sia/57 vac­
cine. T h e  prom ising results from these ex­
perim ents led to the developm ent of large- 
scale m ethods for the production  of de­
soxycholate split influenza virus vaccines.
A num ber of outbreaks of influenza asso­
ciated w ith A2 virus strains have occurred 
in A ustralia in recent years, and it was 
found th a t m any infants had  experienced 
infections w ith these viruses. Accordingly, 
to evaluate the effectiveness of desoxycho­
late d isrup ted  vaccines, a vaccine was p re ­
pared from the A/Swine (Shope) stra in  and 
used for fu rth e r studies in hum ans. T h e  
anti-haem agglutin in  antibody response to 
this sp lit vaccine in mice was somewhat 
lower than  th a t of the un treated  vaccine 
when m easured after single doses were in ­
jected. T h e  difference was m ore pronounced 
with the h igher d ilu tions (lower doses), bu t 
after second injections a t the  same dose 
levels the antibody responses were com­
parable  w ith bo th  the split and the u n ­
treated  vaccines.
No adverse reactions were observed when
this desoxycholate split vaccine was injected 
in to  infants, even when a dose equivalent 
to !500 CCA (chick cell agg lutinating  units) 
was used. T h e  anti-haem agglutin in  a n ti­
body response following a single injection 
was low bu t was detectable in all cases. 
Excellent antibody titres were obtained, 
and no adverse reactions occurred when 
second doses of the  split vaccine were given. 
Sim ilar results were obtained when the 
split vaccine was studied in young adults.
T h e  equivalent of six m illion ad u lt doses 
of desoxycholate d isrup ted  A 2/H ong Kong 
vaccine have recently been prepared  and 
used in Australia. A small num ber of possi­
ble reactions (including m ild soreness at 
the site of injection) have been reported. 
T h e  absence of toxicity of the desoxycholate 
split vaccine has again been dem onstrated 
in infants. A lthough clinical influenza asso­
ciated with A 2 /H ong  Kong viruses has oc­
curred sporadically ever since these viruses 
reached Australia in August 1968 and a l­
though there has been some increase in the 
num ber of cases w ith the advent of w inter 
in 1969, no outbreak of epidem ic p ro p o r­
tions has occurred in this country. A n u m ­
ber of field trials have been set up  to study 
the effectiveness of the desoxycholate split 
A 2/H ong Kong vaccine, bu t w hether the in ­
cidence of influenza will be large enough 





F utu re  Influenza Vaccines and  th e  Use of Genetic R ecom binants
by
Edwin D. K ilbourne: New York, New York, U.S.A.
I t  is im p o rtan t to recognize th a t influ­
enza vaccines of the past and present are, 
in fact, em pirically selected genetic viral 
variants w ith desirable properties; i.e., 
op tim al grow th characteristics, “a tten u a­
tio n ” of virulence, therm al stability, and 
requisite  antigenicity . These variants have 
usually been selected unsystem atically, on 
a h it o r miss basis, from uncloned viral 
stocks of variable history by such em piric 
m aneuvers as m ouse lung  passage to in ­
crease viral yield in chick embryos.
Obviously, it is m ore sensible to a ttem pt 
a correlation of identifiable genetic a ttr i­
butes (markers) of the  virus w ith requisite 
vaccine properties. T h en  one can proceed 
to genetically m anipu late  the  virus for 
selection of optim al clones: 1) by screening 
of m ultip le  viral clones, 2) by chemically 
induced m uta tion  a n d /o r  selection through 
environm ental pressures (e.g., tem perature  
sensitive m utants) o r 3) by genetic recom bi­
nation  of viruses.
R ecom bination is analogous to sexual 
reproduction  in  its po ten tial for the im ­
m ediate, one-step reassortm ent and com­
bination  of genes and gene products. Thus, 
deliberate m ating  of two o r m ore viruses— 
each bearing a desired tra it—can be effected 
and ap p ropria te  progeny virus selected 
(w ithout need for tedious "ad ap ta tio n ” 
un til ap p ropria te  m utan ts—if any—are 
m anifest). I t  is predictable th a t recom bina­
tion, w ith its red istribu tion  of genes, will 
lessen the p robability  of expression of any 
polygenic characteristic such as virulence. 
T herefore, a k ind  of " in stan t a tten u atio n ” 
can be provided by recom bining wild type 
w ith established laboratory strains of lesser 
virulence and then selecting ou t virus of
the required  antigenicity, e.g., Ax V irl Vir2 
Vir3 (virulent) X A2 A virl Avir2 Avir3 -» 
Ax Avirl Vir2 Avir3 (avirulent). However, 
new phenotypes can arise w ith  recom bina­
tion, so the possibility of increased v iru ­
lence cannot be completely excluded.
In practice, recom bination has already 
produced vaccine virus of requisite  a n ti­
genicity (Hong Kong-like) and chick em ­
bryo growth capacity (A0/PR8-like) by dual 
infection w ith these viruses and selection 
against the A 0/PR 8 paren t. T h is  recom bi­
nant, X-31, was isolated w ith in  2 weeks of 
the in itiation  of the experim ent. Its yields 
in chick embryos exceed th a t of any em ­
pirically adap ted  commercial strain  th a t 
we have exam ined, and the recom binant 
grows equally  well a t 33° and 35°C.
O ther po ten tial and “an tic ipatory” ap p li­
cations of recom bination to vaccine p ro ­
duction include: 1) establishm ent of a 
“lib ra ry ” of prefabricated  recom binants in 
an a ttem p t to antic ipate  recom bination in 
n a tu re  of antigens presently known which 
may lead to the evolution of new variants;
2) storage in the  library  of pedigreed high 
yield paren tal viruses ready for recom bina­
tion w ith new strains (hum an o r anim al) 
as they evolve to effect their rapid  “adap ta ­
tio n ” to the vaccine-producing host system;
3) repeated recom bination perhaps to re ­
veal "new ” antigens. As envelope polypep­
tides coded by the reassorted genes are pu t 
together in differing context, new avidity, 
reactivity, or even new antigenicity  may 
emerge. W hether o r no t recom bination is 
the m echanism  of evolution of new strains 
in natu re , the same trick can be tu rned  in 
the laboratory to the detrim en t of influenza 
and the benefit of m an.
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T h e  R ole of A ntineuram inidase A ntibody in Im m unity  to Influenza Virus Infection
by
Jerom e L. Scliulman; New York, New York, U.S.A.
Session V
Im m unity  in influenza has generally been 
a ttrib u ted  to the presence of antibody to 
viral hem agglutin in  in sera o r respiratory 
secretions of previously infected o r im m u­
nized subjects, and changes in antigenic 
s tructure  have been assessed prim arily  by 
sim ilarities and differences of hem agglu­
tin in  antigens in hém agglu tination-inh ib i­
tions tests.
However, influenza virus possesses a sec­
ond virus-coded pro tein  antigen, neu ­
ram inidase, in its envelope, and following 
infection or paren tera l im m unization of 
m an and of laboratory anim als, antibody 
specific for viral neuram inidase is p ro ­
duced. A lthough the protective effects of 
antineuram inidase  antibody have not been 
m easured systematically in m an, antibody 
specific for neuram inidase has been shown 
to in h ib it virus replication and to prevent 
lung lesions in im m unized mice challenged 
w ith a virus containing an antigenically 
sim ilar enzyme.
A ntigenic variations of the two virus- 
coded envelope proteins occur independ­
ently in natu re , resulting  in new viruses 
which differ from o lder strains m ore with 
respect to one antigen than  the other. In 
particu lar, the H ong Kong/68 virus pos­
sesses a hem agglutinin antigen m arkedly 
different from antigens of previous A2 
strains, whereas its neuram inidase has been 
shown in enzyme inh ib ition  and p laque 
size reduction (PSR) assays to be indis­
tinguishable from the enzyme antigens of 
1967-1968 A2 viruses and to be antigenically 
related, b u t not identical to, the  enzyme of 
A 2/Japan/305/57 virus.
T h e  influence of these antigenic re la tion ­
ships on im m unity in mice challenged with 
Hong Kong virus was investigated by using 
recom binant viruses in which hem agglu­
tin in  and neuram inidase antigens of H ong
Kong virus, and two previously isolated 
strains of influenza A2 virus were segre­
gated by recom bination w ith influenza 
AO/NWS virus. Im m unization with inacti­
vated A 2/Japan/305/57  and A 2/E ngland/67 
viruses provided no more protection against 
H ong Kong virus challenge than  im m uniza­
tion w ith hybrid  viruses possessing the en­
zymes b u t no t the hem agglutin in  antigens 
of the two A2 strains, and no protection 
was observed in mice im m unized w ith the 
p aren t A2 viruses challenged w ith a hybrid 
virus possessing the  H ong Kong virus 
hem agglutin in  and the enzyme of AO/NWS 
(Hong Kong e).
In  addition , in studies of the effects of 
im m unity on transmission of influenza virus 
infection in mice, antineuram inidase  a n ti­
body reduced the capacity to transm it in ­
fection b u t d id  not affect susceptibility  to 
the in itiation  of infection, whereas a n ti­
hem agglutinin antibody reduced suscepti­
b ility  to the in itiation  of infection b u t did 
not influence the capacity for transmission.
T w o im plications which derive from these 
observations are: 1) the  taxonom y of in ­
fluenza viruses should include antigenic 
analyses of bo th  surface antigens; 2) the 
protective effects and du ra tio n  of antibody 
to neuram inidase m ust be investigated sys­
tem atically in m an, and the results of such 
studies should be reflected in the choice of 
strains and the standardization  of virus 
pools employed in vaccines.
Finally, a purified neuram inidase vac­
cine m ight provide a useful epidem iologic 
tool. Mass im m unization w ith such a vac­
cine m ight protect indiv idual vaccinees and 
th rough  its effects on transmission induce 
hard im m unity  w ithou t accelerating the 
emergence of new viruses with antigenic­




New C riteria  for the Selection of Vaccine Strains 
by
S. Fazekas de St. G roth ; Sydney, Australia
Serological crossing am ong influenza vi­
ruses is usually asymmetric: an antiserum  to 
virus X will neutralize virus Y relatively 
b e tte r than  an anti-Y  serum  neutralizes 
virus X. T h is  rela tionsh ip  may be d e ­
scribed by calling virus X senior to virus Y. 
T h e  phenom enon is based on the fact th a t 
a lthough the bulk of a senior antibody 
population  participates in cross-reactions, 
only a small fraction of ju n io r antibody 
populations can cross react.
W hen a ju n io r virus is grown in the 
presence of hom ologous antibody, m utan ts 
are selected, all of whom are senior to their 
paren t. Such an experim ent mimics the 
evolution of epidem ic strains, since the 
historical sequence w ith in  each subtype of 
influenza A parallels the o rder of seniority.
Cross-reactions between subtypes are dis­
tan t—less than  5% of the respective p o p u la ­
tions cross react—and may be in terpreted  
as occurring between antigens which differ 
by a double m utation . Such m utan ts can 
be selected, rarely, from senior viruses 
grown un d er hom ologous antibody. T o ­
wards the end of the reign of a subtype 
"bridg ing  antigens” may be isolated in the
field: these are the only m em bers of that 
subtype which give close cross-reactions also 
w ith the next subtype.
W hen an anim al im m une to a ju n io r 
virus is vaccinated w ith a senior antigen, 
it responds by producing antibody th a t 
reacts b e tte r w ith the ju n io r antigen than  
w ith the vaccinating senior antigen. T h is 
is a m anifestation of O riginal Antigenic Sin 
in its classical form. W hen basic im m unity 
against a senior antigen is boosted w ith a 
related antigen, the response is usually at 
least as good against the boosting antigen 
as it is against the prim ary antigen. T h u s 
Original A ntigenic Sin is seen here in a 
modified, venial form.
On this evidence the use of prospective  
vaccines will be proposed. Such vaccines 
would contain a m ix tu re  of senior m utan ts 
selected under antibody pressure from the 
last epidem ic strain. By this means evolu­
tionary antigenic changes m ight be an tic i­
pated and countered, and the vaccination 
itself would no t establish an O riginal A nti­
genic Sin that, based on a ju n io r antigen, 
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T h e  A ntiviral Activity of the  Isoquinolines Fam otine (UK 2054) and 
M em otine (UK 2371) in R espiratory Infections in  M an 
by
G. M. W illiam son and D. Jackson; Sandwich, England
T h e  isoquinolines fam otine—l-(p-chlo- 
rophcnoxy-m ethyl)-3 ,4-dihydroisoquinoline 
hydrochloride (UK 2054)—and memotine-1- 
(p-m ethoxyphenoxym ethyl)—3,4-dihydroiso- 
qu ino line  hydrochloride (l!K  2371)—exhib it 
antiv iral activity in tissue cu ltu re  a t a con­
centration  of 20 ¿¿g or less /m l against a 
range of viruses causing respiratory disease 
in m an. These com pounds have a direct in ­
activating effect upon the m yxovirus and 
param yxovirus particle, whereas the effect 
upon o ther respiratory  viruses is du rin g  the 
viral replicative cycle in tissue culture. T h e  
activity towards m yxovirus b u t not rhino- 
virus has been confirmed in organ culture. 
Both com pounds reduced the yield of virus 
shed from the cultures and protected the 
epithelium  from damage by the influenza 
virus. In vivo activity in mice infected with 
influenza A /PR 8, although not consistently 
reproducible, was significant (p =  0.05) in 
approxim ately 50% of replicate experi­
m ents. T hese findings, coupled w ith the 
low toxicity of these compounds, encour­
aged their fu rth e r study in m an.
Studies in m an have embraced challenge, 
prophylactic, and therapeutic  studies with 
both oral (1.0-2.0 g per day) and local 
(nasal instillation  of a solution containing 
4 o r 15 m g/m l) adm inistration  of the com­
pounds.
Challenge studies w ith several strains of
influenza A2 and B have dem onstrated  a 
significant reduction in the ra te  of infection 
w ith influenza B, i.e., fam otine against B / 
England/13/65 and m em otine against B / 
England/101/62 and a lowered ra te  of in ­
fection with influenza A2, i.e., m em otine 
against A 2/L eningrad /4 /65 . In  a challenge 
study with para-influenza type 2 (strain 
D T) no effect w ith the com pound tested, 
i.e., m em otine, was dem onstrable. A lthough 
in challenge experim ents w ith rhinovirus 
the oral adm inistration  of fam otine, the 
m ore active of the two com pounds against 
this virus, had no effect, the nasal instilla­
tion of the com pound did reduce the inci­
dence of clinical sym ptoms b u t not of sero­
logical responses following challenge w ith 
rh inovirus type 2.
In the absence of any m ajor outbreak of 
acute viral respiratory illness du rin g  the 
w inters of 1967/68 and 1968/69, studies 
designed to assess the value of the oral ad ­
m inistration  of e ither com pound for p ro ­
phylaxis have been inconclusive. However, 
the nasal instillation  of fam otine reduced 
somewhat the incidence of symptoms in a 
small institu tiona l outbreak due to the 
Hong Kong influenza virus.
N either com pound has, as yet, been 
shown to be effective in the therapeutic  
treatm ent of acute respiratory illness.
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T h e  E valuation of A m antadine H ydrochloride in the  T rea tm en t of Influenza
by
R. B. H om ick, Y. Togo, V. Felitti, and  M. K aufm an; Baltim ore, M aryland, U.S.A., 
S. M ahler and  D. Iezzoni; W ilm ington, Delaware, U.S.A.
Session VI
A m antadine hydrochloride is the first 
d rug  to show prom ise as a practical a n ti­
influenza agent. Several studies dem on­
stra ting  a prophylactic effect in volunteers 
w ith induced A2 disease as well as in p a ­
tients du rin g  A2 outbreaks created im petus 
for therapeu tic  trials. T h e  widespread A2 
influenza epidem ic th a t occurred early in
1968 provided the opportun ity  for th era ­
peutic  evaluation.
Closed population  groups were selected 
because of the expected short-lived high 
attack  rate , ease of clinical m anagem ent, 
and am ple facilities for collecting serological 
and virological specimens. One hundred  and 
ninety seven inm ates (103 d rug  group and 
94 placebo group) of five prisons in the 
U nited States agreed to partic ipa te  in the 
10-day, double-blind  evaluation of am an ta ­
dine (100 mgm bid). All were proven to 
have A2 influenza disease by significant 
serological response a n d /o r  repeated isola­
tion of the causative virus from  the p h a r­
ynx. Onset of therapy was approxim ately 20
hours a fte r the first subjective awareness 
of illness. Assessment of d rug  effectiveness 
was based on the rap id ity  of the resolution 
of illness. T h ere  were significantly m ore 
d rug-treated  patients than  placebo patients 
in the “ rapid resolver” group, whereas in ­
dividuals receiving placebo dom inated the 
“slow resolver” group. C riteria  for inclu­
sion in these groups will be presented in 
detail. Analysis of febrile responses in d i­
cated am antad ine-treated  patien ts had sig­
nificantly m ore rapid  defervescence. Virus 
isolation studies revealed etiologically re ­
lated virus in 90% of all volunteers du ring  
the first 5 days of therapy. I t  was ap p aren t 
that clinical im provem ent was not corre­
lated with d isappearance of the virus. 
Nevertheless, the trials conducted du rin g  
the influenza season of early 1968 indicated 
the therapeutic  effect of am antad ine hydro­
chloride. T h e  mechanism s involved need 
elucidation. A dm inistration of 100 mgm 




T h e  Prophylactic  Effectiveness of A m antadine in  Volunteers Challenged w ith  A2 Viruses 
and  in  Populations Experiencing an A 2/H ong Kong Influenza Epidem ic
by
A. A. Sinorodinlsev, G. I. K arpuchin , E. G. Shvetsova, A. M. Malysheva, and 
L. Y. Tyros; Leningrad, U.S.S.R.
Session VI
T h e  prophylactic  activity and safety of 
am antad ine hydrochloride were determ ined 
in extensive studies w ith volunteers and in 
epidem iological field trials d u rin g  an  o u t­
break of A 2 /H ong  Kong influenza in L en­
ingrad in Jan u ary  and  February  1969.
Investigations carried ou t in 1967-1968 
0 1 1  591 healthy volunteers (medical students) 
in a double b lind  study  showed am antad ine 
hydrochloride to be an effective p rophy­
lactic d rug  when adm inistered in daily doses 
of 100 to 200 mg for 11 days beginning 24 
hours before challenge w ith aerosols of live 
influenza A2 virus suspensions containing 
e ith e r the A 2/2I/1965 , A2/133/1967, o r the 
A 2/H ong Kong/1968 strain.
In the placebo group 80% of the suscepti­
ble subjects responded to the live influenza 
vaccine challenge w ith general constitu­
tional and catarrha l clinical symptoms of 
various intensity. A m antadine was found 
to prevent clinical illness in 55% of the 
volunteers and to d im inish the severity and 
duration  of the sym ptoms in the subjects 
who became ill, especially in the m ore im ­
m une groups. A m ore pronounced increase 
in the efficacy of am antadine was observed 
when it was preceded by live influenza vac­
cination.
Studies of the prophylactic effectiveness 
of the drug, carried ou t on 10,053 persons 
du rin g  an extensive outbreak of A 2/H ong 
Kong influenza in Leningrad, have shown 
the regular reduction of influenza cases in 
eight sim ilar institu tions w ith a m ean index 
of 1.95-2.15 am ong subjects who received a 
daily dose of 100 mg am antadine. R egular 
adm inistration  of am antad ine reduced not 
only the  incidence of influenza infection 
b u t also the severity and du ra tio n  of symp­
toms in those subjects who became ill.
T h e  num ber of com plaints of various side 
effects (sleep disturbances and others) 
am ong persons receiving am antad ine was 
too insignificant when com pared to the 
num ber in the placebo group  for any con­
traindication  to the wide general p rophy­





Study of 1-Adam antanam ine H ydrochloride Used Prophylactically during  
the  H ong Kong Influenza Epidem ic in the Family E nvironm ent
by
A. W. G albraith ; Macclesfield, England
T h e  design of this study follows closely 
that reported  at the Second Conference on 
A ntiviral Substances held Ju n e  16, 1969, in 
New York City.
Seventy-two family doctors th roughou t 
G reat Britain volunteered to take pa rt in 
the investigation of an influenzal epidem ic 
occurring d u rin g  the w inter of 1968/69. 
Each was supplied w ith record forms, sy­
ringes, and active or placebo A m antadine 
capsules in code-labelled containers.
W hen a doctor saw an influenza pa tien t 
and considered the family suitable for in ­
clusion in the study, a specimen of venous 
blood was taken from  each m em ber and 
sent to Sheffield Virus Laboratory in a 
special container.
T h e  capsules were then d istribu ted , and
the dose taken was 100 mg every 12 hours 
for 10 days by adu lts and proportionally  
less by children. T h e  index p a tien t kept a 
record of his tem perature  and symptoms. 
O ther m em bers of the family who subse­
quently  became ill d id  likewise.
A pproxim ately 3 weeks after the first 
venipuncture, a second specimen was ob ­
tained and antibody level to H ong Kong 
influenza virus was m easured.
Since the d istribu tion  of the outbreak in 
G reat Britain was patchy, only 29 family 
doctors saw sufficient cases of influenza to 
con tribu te  results. T h e  total nu m b er of 
individuals included was 252, and the 




Observations on the Use of In terferon  in the  Prophylaxis of Influenza
by
V. D. Soloviev; Moscow, U.S.S.R.
Session VI
T h e  first observations on the prophylactic 
and therapeu tic  adm in istration  of interferon 
to hum an volunteers challenged with vac­
cinal strains of influenza A2 virus were 
m ade in 1965-66. T h e  in terferon had been 
prepared  from hum an blood leucocytes sub­
jected to treatm ent with Newcastle disease 
virus. T h e  effectiveness of the interferon 
was determ ined on the basis of reisolation 
of the virus from the up p er respiratory tract 
of the treated  volunteers and from increased 
antibody levels in their blood. A total of 
400 volunteers were observed. T h e  observa­
tions enabled investigators to determ ine 
the m inim al prophylactic dose of the p rep ­
aration , to test the in tranasal m ethod of its 
application , and to find ou t th a t the best 
prophylactic  effect was a tta ined  w ith re ­
peated introduction  of the interferon.
A production  laboratory for in terferon 
biosynthesis set up  a t the Gamaleya In sti­
tu te  for Epidemiology and Microbiology 
had prepared sufficient quan tities of the 
leucocyte in terferon for epidem iological in ­
vestigation by specialists of the C entral In ­
stitu te  of Epidemiology, M inistry of Public 
H ealth , U.S.S.R., and the  N. F. Gamaleya 
Institu te , the In stitu te  of Pediactrics, and 
the Virology Institu te , Academy of Medical 
Sciences, U.S.S.R.
Epidem iological observations carried ou t 
in 1967-68 involved 3,500 persons of differ­
en t ages. T hose in the experim ental groups 
were given interferon; those in the control 
groups received a placebo. T h e  results 
showed th a t in terferon is effective and com­
pletely safe for repeated adm inistration  to 
individuals of all ages, including newborns.
T h e  most extensive controlled observa­
tions were m ade in 1969 durin g  the last 
epidem ic caused by the  A 2 /H ong  Kong/68 
virus. T h e  epidem ic of H ong Kong influ­
enza took place in January-February , 1969, 
lasted for 1 m onth , and revealed no 
substantial differences in the clinical course 
of the disease from th a t of the epidemics 
of preceding years. However, virological
investigations have shown an unusually 
high percentage of virus isolations from 
p a tien ts’ respiratory tracts—reaching 80%— 
as well as some notable  distinctions in p ro p ­
erties of the isolated strains in comparison 
with their predecessors.
More than  14,000 people of varying ages 
were included in the interferon prophylaxis 
study, the collectives having high, m edium , 
and low incidence of the disease. T h e  ob ­
servations were m ade u n d e r controlled con­
ditions and a placebo was adm inistered to 
control groups of com parable size and 
composition. T h e  effectiveness of interferon 
prophylaxis, as shown in reduced disease 
rates in groups given the in terferon as 
com pared w ith rates in control groups, 
varied from 44.8 to 73.8%.
Results suggest the following conclusions: 
first, in terferon prophylaxis of H ong Kong 
influenza in children and adults is u n ­
doubtedly  effective; and, second, the p re p ­
aration  is completely safe.
W e believe th a t the prophylactic effect is 
due not only to the action of the  exogenous 
interferon itself bu t also to th a t of endo­
genous in terferon produced by cells of the 
respiratory tract. M axim al prophylactic 
effectiveness of the artifically in troduced 
interferon is probably a tta ined  when an 
indiv idual is infected and a laten t infectious 
process develops in the organism, un d er the 
in terferon protection, with virus m ultip lica­
tion which, w ithout p roducing symptoms 
of the disease, serves to induce interferon 
production  by cells in the mucosae of the 
respiratory tract.
Separate studies have established that the 
production of endogenous in terferon is de ­
pendent on the organism ’s indiv idual ab il­
ity. T h is has been shown in experim ents 
with anim als of different species as well as 
in m an. T h e  p roportion  of in terferon-re­
fractive individuals in populations varied 
from 12 to 30%. T h is finding should be 
taken into account in evaluating the final 
results obtained in the study of interferon
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as an influenza prophylaxis.
Sim ilarly, the  different influenza virus 
strains isolated d u rin g  the epidem ic of 1969 
d id  not have equal interferonogenicity. T h e  
interferon-positive (I -{-) and interferon- 
negative (I —) strains of the  H ong Kong 
A2 virus also appeared  to be different in 
neuram inidase activity, therm ostability , and 
pathogenicity  to volunteers.
Besides the native leucocyte interferon, a 
concentrated interferon p repara tion  has
been tested for the trea tm en t of influenza 
patients in lim ited  clinical observations. It 
has produced prom ising results.
T h e  general positive estim ation of in te r­
feron prophylaxis should be supplem ented 
by the prospect of the association of in te r­
feron with am antadine. Experim ents in 
vitro in tissue culture, in mice, and in 
lim ited observations in m an suggest a fav­





T h e  Effect of an  In terferon  Inducer on Influenza Virus 
by
David A. H ill, Samuel Baron, and R obert M. Chanock; Bethesda, M aryland, U.S.A.
T h e  synthetic d o u b les tran d ed  RNA 
composed of polyriboinosinic acid and poly- 
ribocytodylic acid (In • Cn) is a po ten t in ­
ducer of in terferon and of in v itro  and 
in vivo resistance to viral infections. Incu­
bation of hum an embryonic kidney cells 
w ith In ■ Cn caused resistance to subsequent 
challenge w ith two strains of influenza A2 
virus (Hong Kong/68 and Ann A rbor/60). 
T en  jag In • Cn per nil in m aintenance 
m edia for 12 hours caused 100% protection; 
1.0 ng per ml caused 50% reduction in 
hem adsorption. Sim ilar levels of protection 
were found w ith o th er common hum an 
respiratory virus pathogens. T h e  level of 
In*  Cn required  to induce com plete in h ib i­
tion of virus replication in these hum an 
cells was 50 times less than  th a t requ ired  to 
induce detectable levels of interferon in 
the cu ltu re  m edium .
T h e  effect of In • Cn on influenza virus 
infection in vivo was studied in mice with 
a strain  of influenza A2 virus (Taiw an/64) 
which was adap ted  to be pathogenic for 
mice. T h e  in tranasal adm inistration  of 25 
to 50 fig of In • Cn up to 30 hours before 
in tranasal challenge w ith 2 to 10 ID 50 of 
influenza virus caused a significant reduction 
in the incidence and extent of pneum onic 
lesions in the mice. T h e  incidence of p n eu ­
m onic lesions was reduced from 87% (26 of 
30) in un treated  controls to 28% (13 of 47) 
in treated mice; the m ean lesion score was
reduced from 2.5 to 0.3. T h e  use of a low 
challenge dose of virus was critical in dem ­
onstra ting  a protective effect of In  • Cn; 
when mice were challenged w ith m ore than  
100 ID M of virus, no significant protection 
was seen. A dm inistration of In  • Cn by 
in traperitoneal injection was not effective in 
protecting  against in tranasal challenge. 
T h e  greater effectiveness of in tranasal over 
in traperitonea l adm inistration  may be ex­
plained by differences in the d istribu tion  
and du ra tion  of interferon production  fol­
lowing the different routes of adm in istra ­
tion. After in tranasal instillation of 50 ^g 
In  • Cn, a peak serum  level of 1,000 units 
of interferon per ml was reached and de ­
creased only to 100 units after 48 hours, 
whereas, after in traperitonea l injection, a 
peak serum  level of 10,000 units was reached 
after 6 hours, b u t decreased to an u nde­
tectable level at 48 hours. T h e  in terferon 
m easured in hom ogenized lung  tissue 
reached a peak tite r  of 3,500 units per 
gram  (3.5 times the serum  level) 6 hours 
afte r in tranasal instillation of In  • Cn; a 
peak tite r of 1,000 un its (0.1 times the 
serum  level) was reached in 6 hours and 
fell to an undetectable level a t 48 hours.
On the basis of findings w ith influenza 
and o ther hum an respiratory virus p a th o ­
gens, we are evaluating  the poten tial use 
of In • Cn in the  prevention and treatm ent 
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